The QualityStocks Daily Friday, May 14th, 2021

Today's Top 3 Investment Newsletters

Tip.us(NBDR) $0.0300 +71.43%

QualityStocks(RGRX) $0.2890 +37.00%

MarketBeat(OSS) $5.4300 +23.41%

The QualityStocks Daily Stock List

Timber Pharmaceuticals Inc. (NYSE American: TMBR)

InvestorPlace, StockMarketWatch, INO Market Report and Darwin Investing Network reported earlier on Timber Pharmaceuticals Inc. (TMBR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Timber Pharmaceuticals Inc. (NYSE American: TMBR) (FRA: BPC2) is a biopharmaceutical firm that is focused on developing and commercializing treatments targeting rare as well orphan dermatological conditions.

The company, founded in 2019 and having its headquarters in New Jersey, explains that they focus on rare skin diseases since this category of diseases hasn’t been given a lot of attention by the medical or pharmaceutical world. For example, while more than 450 rare skin diseases have been profiled, only 8 have remedies which are approved by the FDA and a total of 17 treatments exist for those 8 conditions.

Timber Pharmaceuticals was created as a result of collaborations of three firms which have a proven track record of taking drug candidates through the different phases of development right up to securing regulatory approval. Currently, the company has a pipeline of three formulations which all qualify to be designated as orphan drugs since they seek to address an unmet clinical need. The first candidate is named TMB-001 (topical isotretinoin) indicated to treat moderate and severe forms of congenital ichthyosis (CI). This group of genetic disorders causes the skin to thicken, dry up and develop scales. Phase 2 clinical studies are ongoing for this candidate.

The second product candidate is TMB-002 (topical rapamycin) indicated for the treatment of facial angiofibromas. There is no commercially available treatment for this condition, and TMB-002 is undergoing phase 2b clinical trials on its journey to being approved for use to address this unmet need. The third candidate is TMB-003 which is still in the preclinical phase of development. Timber Pharmaceuticals hopes to submit an IND (investigational new drug) application to the FDA by the end of 2021. The drug is expected to be useful in the treatment of scleroderma that is localized.

Given that the company targets conditions for which no treatment exists, the success of any of its current candidates undergoing trials will result in massive growth of the company’s stocks.

Timber Pharmaceuticals Inc. (TMBR), closed Friday’s trading session at $1.12, up 5.6604%, on 923,310 volume with 2,155 trades. The average volume for the last 3 months is 7,235,090 and the stock's 52-week low/high is $0.665099978/$10.4399995.

Liquidia Corp. (NASDAQ: LQDA)

MarketClub Analysis, StockMarketWatch, QualityStocks, MarketBeat, BUYINS.NET, Zacks, TradersPro, StreetInsider and Stock Market Watch reported earlier on Liquidia Corp. (LQDA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Liquidia Corp. (NASDAQ: LQDA) (FRA: LT4) is a late-stage clinical biopharm company which develops and commercializes products using its proprietary PRINT technology. The firm was founded in 2004 and has its headquarters in North Carolina, USA. The company prides itself in bringing novel therapeutics to the patients who need them most, and to the healthcare providers who are committed to taking care of those patients.

At the moment, Liquidia is currently focused on improving the precision and outcomes of pulmonary arterial hypertension (PAH) treatment. The company does this largely through its subsidiaries which include Liquidia Technologies Inc. as well as RareGen, LLC.

The firm is currently engaged in taking two drug candidates through the development process. The first is LIQ861, which is an inhaled dry powder made from treprostinil. This formulation is intended to improve the rate at which the drug is delivered deep into the lungs in addition to making it possible for higher doses of this drug to get into the furthest sections of a patient’s lungs. By making these tweaks to the way patients are treated, Liquidia hopes to help the nearly 30,000 patients in the U.S. alone who suffer from the potentially fatal PAH (pulmonary arterial hypertension) disease. This candidate has completed phase 3 clinical trials.

The second candidate is LIQ865. It is designed to deliver the non-opioid anesthetic bupivacaine for the purposes of treating localized post-surgical procedure pain. A single administration (by continuous infusion with the help of a pump or intravenous infusion by use of a catheter) of this drug candidate can manage this type of pain for 3-5 days, thereby eliminating the need for patients to get daily doses of bupivacaine. So far, two phase 1 clinical studies have been completed in addition to toxicological studies as the candidate is prepared for phase 2 trials.

When these candidates complete the clinical phase of their development successfully, the company will be in position to deliver greater shareholder value through serving PAH patients better.

Liquidia Corp. (LQDA), closed Thursday’s trading session at $1.16, off by 7.9365%, on 830,388 volume. The average volume for the last 3 months is 3,891,224 and the stock's 52-week low/high is $1.05999994/$2.57999992.

Enveric Biosciences Inc. (NASDAQ: ENVB)

MarketClub Analysis, INO Market Report, Schaeffer's and QualityStocks reported earlier on Enveric Biosciences Inc. (ENVB), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Enveric Biosciences Inc. (NASDAQ: ENVB) (FRA: SLZ) is a patient-focused biotech firm specialized in enhancing the lives of patients who have suffered the adverse effects of undergoing conventional cancer treatment. The firm has a goal of testing different natural compounds, especially cannabinoids, in order to develop novel medicinal formulations that clinicians can prescribe to patients exhibiting symptoms of adverse effects of cancer treatment.

The company, which was founded in 1994 and is headquartered in Naples, Florida relies on its extensive global network of oncologists and scientists to leverage the innovative clinical developments within the cannabinoids space to identify opportunities to come up with cannabinoid-based formulations.

Enveric Biosciences has a pipeline of different products which are in varying stages of development. For example, its cannabinoid-based formulation for glioblastoma multiforme is in preclinical development, and so is its candidate for radiation dermatitis. Another candidate targeting chemotherapy-triggered peripheral neuropathy is still in the discovery phase.

At the end of 2020, David Johnson, the Chairman and CEO of the company gave the shareholders of the company an update about the performance of the firm thus far, and he gave highlights of what the company looks to achieve in the years to come, beginning with 2021. In Q1 of 2021, the company acquired an exclusive and perpetual license to five cannabinoid molecules from Diverse Biotech. These will help Enveric Biosciences access scientists and data crucial to the preclinical and clinical development of drugs that can alleviate some side effects of cancer treatment.

Additionally, the firm launched a development collaboration as well as an exclusive supply agreement with PureForm Global in the quest of the two firms to speed up the development of formulations geared at treating the pain and inflammation caused by cancer treatment.

If those development programs are successful, they will address a massive need by patients to utilize plant-based products while managing the different side effects triggered by the existing cancer therapies. Investors are bound to benefit as this demand is met by the products developed by the company.

Enveric Biosciences Inc. (ENVB), closed Friday’s trading session at $1.91, up 0.526316%, on 447,018 volume with 1,729 trades. The average volume for the last 3 months is 6,197,523 and the stock's 52-week low/high is $1.85000002/$21.2000007.

Tyme Technologies Inc. (NASDAQ: TYME)

MarketClub Analysis, StockMarketWatch, MarketBeat, PoliticsAndMyPortfolio, TraderPower, BUYINS.NET, Wall Street Mover, Trades Of The Day, StreetInsider, Schaeffer's and Investopedia reported previously on Tyme Technologies Inc. (TYME), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Tyme Technologies Inc. (NASDAQ: TYME) (FRA: RFL) is a clinical stage biotechnology firm that is engaged in the discovery and development of cancer therapies for the treatment of various cancers, like hematologic cancers, in the United States.

The firm has its headquarters in New York and was incorporated in 2011, on November 22 by Michael Demurjiana and Steve Hoffman. Prior to its name change, the firm was known as Global Group Enterprises Corp. It serves consumers in the state of New York.

The enterprise is party to a strategic collaboration with Eagle Pharmaceuticals Inc. for the advancement of its oral SM-88 candidate for treating cancer patients; and a research collaboration with Mayo clinic and NYU Langone Health, for the development of treatments for various metastatic cancers, such as pancreatic cancer.

The company’s product pipeline is made up of a CMBT (cancer metabolism-based therapy) dubbed SM-88, which is currently undergoing a phase 2/3 clinical trial to test its effectiveness in treating fifteen types of cancer including lymphoma, sarcoma, prostate, breast, lung and pancreatic. The candidate is available in transdermal, intranasal and injectable formulations. Other products include another CMBT compound dubbed TYME-18, that’s in the preclinical stage for solid tumor treatment.

The firm recently appointed a new chief medical officer who will provide direction and leadership for all medical and preclinical programs in development. The appointed chief medical officer has under his belt over 2 decades of medical experience in industry and academia, which will benefit the company greatly and enable them to advance their pipeline.

Tyme Technologies Inc. (TYME), closed Friday’s trading session at $1.23, up 7.8947%, on 3,202,766 volume with 7,623 trades. The average volume for the last 3 months is 3,209,668 and the stock's 52-week low/high is $0.850000023/$4.98999977.

Trecora Resources (NYSE: TREC)

RedChip, Money Morning, Daily Trade Alert, StreetInsider, MarketBeat, Total Wealth, TopPennyStockMovers, The Wall Street Transcript, Street Insider, StockOodles, Marketbeat.com, Investopedia and Direction Alerts reported beforehand on Trecora Resources (TREC), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Trecora Resources (NYSE: TREC) (FRA: A34) is focused on the sale and manufacture of synthetic waxes and petrochemical products, as well as providing custom processing services.

The firm is based in Sugar Land, Texas and was incorporated in 1967, on May 4. Formerly known as Arabian American Development, the firm serves consumers in the United States and generates most of its revenue from its specialty petrochemical segment.

The enterprise operates through the specialty waxes segment and the petrochemical segment. The latter specialty segment is engaged in the production of high purity hydrocarbons, among many more petroleum based products, which include hexane, isohexane, normal pentane and isopentane. This segment operates through SHR (South Hampton Resources Inc.). SHR is owned by Texas Oil and Chemical Co., a subsidiary. On the other hand, the former segment offers custom processing services and also engages in the manufacture of poly alpha olefin waxes and specialty polyethylene.

The firm operates and owns a facility found north of Beaumont, in southeast Texas, which manufactures high-purity hydrocarbons and other petrochemical products.

The company recently appointed a new chief manufacturing officer, who has over 3 decades’ worth of experience in extensive chemical manufacturing from some of the leading firms in the industry. This move will ensure that there’s decisive and effective leadership in operations, which will help drive structural and strategic change, while also decreasing maintenance costs and improving reliability. Apart from making the company’s manufacturing processes stronger, safer and more innovative, this will also enable the company to achieve its overall goals.

Trecora Resources (TREC), closed Friday’s trading session at $8.07, up 2.1519%, on 152,456 volume with 1,390 trades. The average volume for the last 3 months is 123,979 and the stock's 52-week low/high is $4.67000007/$8.35000038.

Doubleview Capital Corp. (DBLVF)

We reported earlier on Doubleview Capital Corp. (DBLVF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Doubleview Capital Corp. is a mineral resource exploration and development company listed on the OTC Markets. The Company identifies, acquires and finances precious and base metal exploration projects in North America, particularly in the Province of British Columbia. It explores for copper, gold, silver, and zinc deposits. The Company’s projects include the Hat Deposit, Red Spring, and Mt. Milligan North. Incorporated in 2008, Doubleview Capital has its corporate headquarters in Vancouver, British Columbia.

The Company’s goal is to aggressively acquire and develop quality and highly prospective mineral projects in mining friendly parts of Canada and specifically in British Columbia. The Hat Gold Rich Porphyry Copper Project situated in Northwest British Columbia (Alkalic Porphyry Deposit type Model) was discovered in 2013/2014 by Doubleview Capital.

Red Spring is located in Northwest British Columbia. It features Copper, Gold, Silver and Zinc. The Mt Milligan North Property is located in Central British Columbia. It is an Alkalic Porphyry Deposit type Model.

Doubleview Capital previously announced the latest assay results from its Hat Gold-Copper Porphyry property positioned in northwestern British Columbia. Core samples from drill holes H026 and H031 extend the Lisle Zone mineralization to the south and at depth with strong gold and copper values and important silver, cobalt, and palladium.

Drill hole H026 was successfully deepened so as to probe what appeared from geophysical data to indicate the vertical continuation of the Lisle Zone. H026 has now extended the Zone to 900 meters from surface. It has confirmed the reliability of the 3D induced polarization survey data. H031 was collared 215 meters south of prior drill holes (550m southwest of drill hole H023) and extended the north-south dimension of the Lisle Deposit to 820 meters. Doubleview Capital completed 2,227 meters drilling in five drill holes. Drill hole H032 was abandoned because of drilling technical issues.

Doubleview Capital Corp. (DBLVF), closed Friday’s trading session at $0.4924, up 23.1616%, on 213,163 volume with 51 trades. The average volume for the last 3 months is 126,560 and the stock's 52-week low/high is $0.0625/$0.500720024.

Cardiff Lexington Corporation (CDIX)

We reported previously on Cardiff Lexington Corporation (CDIX), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Cardiff Lexington Corporation is a diversified financial services holding company listed on the OTC Markets. It mainly focuses on the tax, debt, and real estate sectors. It is implementing a buy and build strategy taking advantage of proven management in private companies that become subsidiaries. The Company targets acquisitions of mature, high growth, niche companies.

Cardiff Lexington has its corporate headquarters in Fort Lauderdale, Florida. The Company previously went by the name Cardiff International, Inc. It changed its name to Cardiff Lexington Corporation in January of 2018. Cardiff Lexington Corporation was established in 2001.

The Company's strategy identifies and empowers select income-producing middle market private businesses and commercial real estate properties. Cardiff Lexington provides these companies the enhanced ability to raise money for operations or expansion, and an equity exit and liquidity strategy for the owner, heirs, and/or Investors. Cardiff also provides a proven experienced Cardiff Lexington management team to spearhead growth and expansion.

For investors, the Company provides a diversified lower risk to protect and safely enhance their investment through continually adding assets and holdings. A strong team of executives and advisors providing expert acquisition, market guidance, and added management value for subsidiaries and investors leads Cardiff Lexington.

Recently, Cardiff Lexington announced that it has divested its holdings in the food services sector. The Company has reached accord in principal with Mr. Frank Repicci and Mr. Gene Romeo respectively whereby Repicci's Italian Ice and Gelato and Romeo's New York Style Pizza will spin out as private companies no longer operating as subsidiaries of Cardiff Lexington.

The Cardiff Lexington Board of Directors has narrowed its forward emphasis to acquisitions in the financial services sector to build upon its tax subsidiaries with related debt, credit, billing, and real estate opportunities.

Mr. Alex Cunningham, Chief Executive Officer of Cardiff Lexington, stated, "Our "Buy and Build" strategy is targeting acquisition of middle market private niche financial service companies and real estate both mature, and, second stage with high growth potential. Repicci's and Romeo's no longer fit within our longer-term strategy and given their impact from COVID-19 for these companies to remain subsidiaries of a public entity exerts additional and unnecessary cost and pressure. This was a difficult decision to sell our food businesses but believe it to be in the best interest of our shareholders…”

Cardiff Lexington Corporation (CDIX), closed Friday’s trading session at $0.0158, up 31.6667%, on 1,316,571 volume with 28 trades. The average volume for the last 3 months is 2,482,210 and the stock's 52-week low/high is $0.0102/$0.865499973.

Jacksam Corporation (JKSM)

QualityStocks and CFN Media Group reported previously on Jacksam Corporation (JKSM), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Jacksam Corporation is a workflow automation company centered on developing machinery and equipment solutions for the cannabis and CBD (cannabidiol) industry. The Company designs and markets proprietary automated vape, POD and cartridge filling/capping equipment for the cannabis industry. It serves the medical cannabis, hemp, and CBD segments of the e-cigarette and vaporizer markets with its oil vaporizer focused products. Jacksam is based in Rancho Santa Margarita, California. The Company lists on the OTC Markets’ OTCQB.

Jacksam’s automated equipment is designed and built in the USA. It carries the only full UL certification in the U.S. Using Jacksam/Convectium's automated equipment, its customers increase output by up to 60 times over hand filling. Jacksam/Convectium is focused on helping its customers automate their workflow and get custom branded products onto dispensary shelves fast. More than 100 companies, including many dominant brands in the space, rely on Jacksam/Convectium for automation of their filling operations.

The Company has adopted an “open source” business model enabling the majority of cannabis and CBD oil producers to benefit from its filling and capping equipment. Jacksam (shifting away from a closed system approach) has made its vape, POD and cartridge trays and equipment compatible with components produced by most of the top international manufacturers.

Recently, Jacksam announced that The Stock Day Podcast welcomed Jacksam Corporation. The President and Chief Executive Officer of the Company, Mr. Mark Adams, joined Stock Day host Everett Jolly. Jolly began the interview by commenting on Jacksam's partnership with Jupiter Research, LLC, and what it means for their future.

Mr. Adams said, "Jupiter is by far the leading C-Cell technology company selling in the United States and abroad. They bring a quality and research and development technology aspect to a partnership that we really value."

Jacksam Corporation (JKSM), closed Friday’s trading session at $0.245, up 36.1111%, on 123,261 volume with 50 trades. The average volume for the last 3 months is 40,907 and the stock's 52-week low/high is $0.05/$0.990000009.

RegeneRx Biopharmaceuticals, Inc. (RGRX)  

QualityStocks, MarketBeat, PennyStockProphet, Penny Pick Finders, TopPennyStockMovers, StockOnion, Stock News Now, SmarTrend Newsletters, Planet Penny Stocks and Buzz Stocks reported previously on RegeneRx Biopharmaceuticals, Inc. (RGRX), and today we report on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, RegeneRx Biopharmaceuticals, Inc.  is a clinical-stage drug development company.  It centers on tissue protection, repair, and regeneration with a  wide-ranging  portfolio of product candidates for first-in-class therapeutic peptides.  The Company’s  mission is to research and develop novel pharmaceuticals, which  protect and repair tissue and organ damage caused by disease, trauma, or other pathology.  RegeneRx Biopharmaceuticals is headquartered in Rockville, Maryland. 

  The Company  holds  manifold  issued patents or filed patent applications worldwide  to enable and protect numerous indications and applications for its product candidates.  At present, RegeneRx has three drug candidates in clinical development for ophthalmic, cardiac,  and dermal indications.

Furthermore, the Company has three active strategic licensing agreements in the U.S, China, and Pan Asia (Korea, Japan, and Australia, among others). In addition, RegeneRx has patents and patent applications covering its products in many nations globally. 

  RegeneRx Biopharmaceuticals is concentrating on moving three distinct Tβ4-based drug candidates through the clinic. These are RGN-137, RGN-259, and RGN-352. RGN-137 is a topical gel formulation of the peptide Tβ4. The Company is developing this as a novel treatment to expedite dermal healing. RGN-137 is a Tβ4-based dermal gel formulation undergoing development for epidermolysis bullosa, which is a rare skin condition.

RegeneRx  Biopharmaceuticals  is focusing on the development of Thymosin beta 4 (a novel therapeutic peptide), for tissue and organ protection, repair and regeneration. RGN-259,  its TB4-based ophthalmic drug candidate, has been designated an orphan drug for the treatment of neurotrophic keratopathy (NK), which is a primary focus of RegeneRx’s clinical development efforts in the U.S.

RegeneRx is also developing RGN-352. RGN-352 is its TB4-based injectable. This is a Phase 2-ready drug candidate designed to be administered systemically to prevent and repair cardiac damage resulting from heart attacks and central nervous system tissue damage associated disorders. These include peripheral neuropathy, multiple sclerosis and traumatic brain injuries - including stroke.

Recently, RegeneRx Biopharmaceuticals announced that Thymosin beta 4 (Tβ4), the active ingredient in RGN-259, a preservative-free ophthalmic eye drop, was the subject of a Keynote Address at the 5th International Symposium of Thymosins in Health and Disease in Washington, DC. The presentation was given by Dr. Gabriel Sosne, an award-winning clinician scientist, Associate Professor in Ophthalmology and Anatomy and Cell Biology at Wayne State University School of Medicine, and a clinician at the Kresge Eye Institute in Detroit, Michigan.

RegeneRx Biopharmaceuticals, Inc. (RGRX), closed Friday’s trading session at $0.289, up 36.9993%, on 712,433 volume with 177 trades. The average volume for the last 3 months is 169,879 and the stock's 52-week low/high is $0.174999997/$0.819999992.

Timberline Resources Corp. (TLRS)  

QualityStocks, Gold Investment Letter, MarketBeat and Marketbeat.com reported previously on Timberline Resources Corp. (TLRS), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Timberline Resources Corp. is a gold exploration and development company. Its  operational focus is Nevada. The Company’s flagship Talapoosa Project is a partially permitted, open-pit, heap leach gold project with low capital and operating costs and strong economics. In addition, Timberline’s exploration efforts have been focused on its 23 square-mile Eureka land package. This is one of the largest remaining undeveloped gold properties in Nevada. OTCQB-listed, Timberline Resources is headquartered in Coeur d’Alene, Idaho.

The Company is refocusing its exploration efforts on advancing the Windfall and Lookout Mountain projects at its Eureka property. This is simultaneous with giving up its option to acquire the Talapoosa project. Regarding the Eureka land package, it includes Timberline’s Lookout Mountain project and a pipeline of earlier-stage projects that feature past gold production, historic gold estimates, and/or drill-indicated gold mineralization. Eureka is on the south end of Nevada’s Battle Mountain/Eureka Trend. 

  Timberline continues to advance its Lookout Mountain and Windfall project areas at Eureka. It purchased a large block of patented and unpatented mining claims in 2012. These comprise mainly the entire Seven Troughs gold mining district near Lovelock in Pershing County, Nevada.

The purchased property package covers 4,100 acres. It consists of 64 patented and 238 unpatented lode mining claims, all which are under a long-term lease agreement, along with 162 additional unpatented lode mining claims.

Timberline Resources previously announced that it closed on the acquisition of ownership interests in two Nevada gold-copper mineral properties in the Battle Mountain mining district in Nevada from Americas Gold Exploration, Inc. (AGEI). This acquisition includes the right to earn into existing Joint Venture agreements with McEwen Mining, Inc. at the Elder Creek Project (Elder Creek Joint Venture), and with Lac Minerals (USA) LLC, a wholly-owned subsidiary of Barrick Gold Corporation (LAC) at the Paiute Project (Paiute Joint Venture).

Timberline Resources Corp. (TLRS), closed Friday’s trading session at $0.2399, up 22.7738%, on 83,328 volume with 34 trades. The average volume for the last 3 months is 122,503 and the stock's 52-week low/high is $0.039999999/$0.396400004.

Leading Edge Materials Corp. (LEMIF)

We reported previously on Leading Edge Materials Corp. (LEMIF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Leading Edge Materials Corp. concentrates on the production of high value critical raw materials for the European market. It has an operating base in the Nordic region. The Company’s flagship asset is the Woxna Graphite production facility in central Sweden targeting the supply of specialty materials for lithium ion battery production. OTCQB-listed, Leading Edge Materials is based in Vancouver, British Columbia.

The Company operates in four divisions: Graphite, Lithium, Rare Earth and Cobalt. Leading Edge’s assets and research focus are towards the raw materials for Li-ion batteries (graphite, lithium, cobalt); materials for high thermal efficiency building products (graphite, silica, nepheline); and materials that improve the efficiency of energy generation (dysprosium, neodymium, hafnium). Its investments are linked to the global shift to low-carbon energy generation and energy storage.

Leading Edge Materials has 100 percent ownership of industry-leading assets in the Nordic region. It has 100 percent ownership of graphite, cobalt, lithium and rare earth element deposits across three mining supportive jurisdictions. In addition, the Company has a unique position in the sustainable supply of critical materials for the high growth lithium ion battery market.

Leading Edge Materials has its Romanian Exploration Alliance. The Exploration Alliance is focused on the discovery and development of lithium ion battery raw materials. The main efforts of the Exploration Alliance as of early November 2018, was directed towards cobalt mineralization within the Upper Cretaceous Carpathian magmatic belt of the Balkan region.

Leading Edge Materials previously provided a summary of test work conducted on graphite from its 100 percent owned Woxna mine in Sweden during last year. With the test program complete, the Company is now moving ahead to an engineering study supporting the installation of a Battery Graphite Demonstration Plant at the Woxna site. The demonstration plant, when installed, will enable process conditions to be optimized and larger volumes of natural graphite anode material to be supplied to prospective lithium ion battery customers.

Leading Edge Materials is advancing a portfolio of European battery raw material projects. These include the fully built and permitted above-mentioned Woxna graphite mine in Sweden, the Bihor Sud cobalt-copper-nickel project in Romania, and the Norra Kärr heavy rare earth element-zirconium-hafnium deposit. All are high merit projects within the European raw material sector.

The Company’s internal corporate Strategic Review firstly highlighted that Leading Edge's combination of discovery-stage and development-stage assets may present different requirements concerning operational structure, capital needs and investor preferences. The Board resolved that the next stage of the Strategic Review will identify and compare opportunities for the Woxna graphite mine.

Potential recommendations from this stage of the Strategic Review may include a transition to a freestanding European company. Additionally, it will consider direct third-party investment into Woxna, horizontal or vertical joint-venture of with aligned parties, or a standalone public listing of Woxna on a Swedish exchange. The Board cautions that there is no assurance or guarantee that any potential transaction identified by the Strategic Review will be pursued.

Leading Edge Materials Corp. (LEMIF), closed Thursday’s trading session at $0.058, up 23.4043%, on 295,900 volume. The average volume for the last 3 months is 85,731 and the stock's 52-week low/high is $0.0302/$0.068999998.

BTCS, Inc. (BTCS)

MarketBeat, QualityStocks, Zacks, The Stock Psycho, AllPennyStocks, Wall Street Mover, Top Gun, StockMister, OTCPicks and HotShotStocks reported previously on BTCS, Inc. (BTCS), and today we report on the Company, here at the QualityStocks Daily Newsletter.

BTCS, Inc. is a blockchain technology focused company headquartered in Silver Spring, Maryland. The Company is an early entrant in the Digital Asset market. In addition, it is one of the first U.S. publicly traded companies engaged with Digital Assets and blockchain technologies. Blockchains are distributed public ledgers, which can fundamentally influence all industries around the world that require trust and rely on or use record keeping. The Company has a record of accomplishment of accurate digital asset trend prediction. BTCS’ shares trade on the OTC Markets Group’s OTCQB.

BTCS’ plan (subject to additional financing) is to create a portfolio of digital assets, such as bitcoin and other "protocol tokens", to provide investors a diversified pure-play exposure to the bitcoin and blockchain industries. The Company’s intention is to acquire digital assets by way of open market purchases; and participating in initial digital asset offerings (or initial coin offerings).

Furthermore, BTCS may acquire digital assets through resuming its transaction verification services business (or mining) via outsourced data centers and earning rewards in digital assets by securing their respective blockchains. Moreover, the Company is concentrating on growth via acquisition.

A blockchain is secured and maintained by a network of specialized servers (nodes) globally. All transactions are publicly available on a blockchain. Transactions undergo verification and confirmation through nodes worldwide before being added to a blockchain.

BTCS recently announced the appointment of Mr. Jonathon R. Read to its Board of Directors. Mr. Read has held many executive positions with domestic and global companies over a career, which spans more than 35 years. Most recently, from 2013 to the present, he has served as Managing Partner of Quadratam1 LLC (Scottsdale, Arizona) a firm specializing in providing financial and organizational consulting services for growth-stage companies in the United States and China

Before that, Mr. Read served as Chief Executive Officer (CEO) or President of Timefire VR, Inc., previously known as EnergyTek Corp. During his tenure, he repositioned, re-financed, and merged the company into an entity centered on the virtual reality sector.

Mr. Charles Allen, BTCS CEO, said, "Jonathon brings a wealth of public company expertise to our board. As we move forward on our plans to build a vertically-integrated operation in the burgeoning blockchain space, Jonathon's experience should add tremendous value."

BTCS, Inc. (BTCS), closed Friday’s trading session at $0.75495, up 34.5722%, on 1,363,010 volume with 793 trades. The average volume for the last 3 months is 1,700,920 and the stock's 52-week low/high is $0.109999999/$3.24.

Featured Whitepapers

A Case for Small & Micro-Cap Investing

Avenel Financial Group’s (AFG) financial research analysts and interns researched the top performing Microcap investors, studied their investments, and analyzed quantitative and qualitative metrics along with the historical performance of this asset class.

Read More...

Featured Whitepaper

XPEL Case Study

Did You Miss Your Opportunity on This 100-Bagger?

As a continuation of our study of Super Compounders we will evaluate one of the more prominent 100-Baggers of the past decade. XPEL technologies is a company that has rose to dominate the niche space of protective films for car paint and has rapidly grown through intelligent capital allocation and acquisitions. Paul Andreola of Smallcap Discoveries first brought this to MicroCapClub in 2013. Attached is an in-depth analysis of its meteoric rise, which we hope will help you to spot the next 100-Bagger.

Read More...

Featured Whitepaper

Quality Shareholders

Lawrence A. Cunningham discussed the makeup of the modern shareholder group in his recent book “Quality Shareholders.” In this paper we briefly discuss the primary takeaways and applications of the concepts in this book and the advantages inherent in the active cultivation of a quality, engaged shareholder cohort. The insights in Cunningham’s book are impactful and may illuminate new strategies for evaluating a firms management.

Managers get the shareholders they deserve.” – Lawrence Cunningham

Read More...

 

The QualityStocks Company Corner

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

After plugging along for more than a century, the internal combustion engine (“ICE”) vehicle is finally being retired. Several countries around the world have pledged to replace the vehicles with zero-emission battery electric vehicles (“BEVs”) over the next decade or two. The industry is still pretty young, however, with electric vehicles (“EVs”) making up only 3% of all the vehicles on the globe. The rapid growth of the electric vehicle industry has attracted the attention of plenty of companies, including those that operate in different sectors. An example is Net Element (NASDAQ: NETE), which is a global provider of value-added financial solutions. The company is set to enter the EV market once its proposed merger with Mullen Technologies Inc. is finalized.

On June 15, 2020, Net Element announced its entry into a binding letter of intent to merge with privately-held Mullen Technologies Inc., a Southern California-based electric vehicle company, in a stock-for-stock reverse merger in which Mullen’s stockholders will receive the majority of the outstanding stock in the post-merger company. The proposed merger is currently pending the execution of a definitive agreement, shareholder vote and regulatory approval.

Net Element Inc. (NASDAQ: NETE) is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. The company’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

Net Element has also launched a blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element chairman and CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked on Deloitte’s Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in both 2017 and 2018, during which the company grew 190 percent and 183 percent, respectively. The company credits its progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

Net Element was also listed among South Florida Business Journal’s 2016 fastest growing technology companies.

Leveraging its suite of application performing interfaces (APIs) and connectors, Net Element powers commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Leading this innovation is chairman and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jeffrey Ginsburg, CPA, and Steven Wolberg, the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations like Aptito to e-commerce and retail payment transaction processing brands like Payonline and Unified Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed Friday’s trading session at $10.84, up 16.4339%, on 335,510 volume with 2,381 trades. The average volume for the last 3 months is 391,368 and the stock's 52-week low/high is $2.0301001/$20.0783996.

Recent News

Infobird Co., Ltd (NASDAQ: IFBD)

The QualityStocks Daily Newsletter would like to spotlight Infobird Co., Ltd (NASDAQ: IFBD).

Infobird (NASDAQ: IFBD), a leading artificial intelligence (“AI”) software-as-a-service (“SaaS”) provider is positioned for opportunity amid a wave of digital transformation sweeping across China. In the last two decades, the company has gleaned tremendous experience and achieved significant technological advances and service capabilities while providing customized SaaS products to some of China’s largest and most demanding financial institutions. With that solid foundation in place, Infobird recently implemented a strategic transition to standardized module SaaS with the intent to expand its customer base and quickly capture additional market share. “Standardized module SaaS has the characteristics of fast scale up and low cost compared to customized SaaS,” reads a recent article on the transition. “The strategic transformation of Infobird from customized SaaS to standardized module SaaS not only replicates its past success serving large financial institutions to large customers across industries, but also promotes its SaaS to many more small and medium-sized enterprises in China.” This enables businesses that cannot afford expensive customized SaaS to benefit from high-quality standard AI-powered SaaS customer engagement solutions.” To view the full article, visit https://ibn.fm/anrP1

Infobird Software (NASDAQ: IFBD), a software-as-a-service (“SaaS”) provider of AI-powered customer engagement solutions in China, offers holistic software solutions to support its growing corporate clientele deliver and manage customer engagement activities from beginning to end of the sales process; the company’s services even extend beyond to pre-sales and post-sales client support and involvement. Infobird combines its proprietary cloud computer structure with patented Voice over Internet Protocol (“VoIP”) and AI and machine learning capabilities as well as a no-code development platform for a flagship customer engagement offering unlike anything else in the industry. For more information, visit the company’s website at www.Infobird.com

Infobird Co., Ltd (NASDAQ: IFBD) is a software-as-a-service (SaaS) provider of AI-powered customer engagement solutions in China. Infobird leverages a self-developed cloud computing structure, AI and machine learning capabilities, patented Voice over Internet Protocol (VoIP) application technologies, a no-code development platform and in-depth industry expertise to best serve its growing client base.

Founded in October 2001, Infobird empowers clients with value-driven business solutions designed to increase revenue, reduce costs and enhance service quality and customer satisfaction. The company currently specializes in corporate clients in finance and a broad array of ancillary industries.

Infobird is headquartered in Beijing, China, and began trading on the Nasdaq Capital Market on April 20, 2021, following an initial public offering of 6.25 million ordinary shares at a public offering price of $4.00 per share, before underwriting discounts and commissions.

Product Offering

Infobird’s flagship customer engagement software can handle both AI Customer Engagement and AI Salesforce Management.

  • AI Customer Engagement
    • Intelligent Omni-Channel Customer Service – This offering allows clients to connect with their customers anytime and anywhere through a comprehensive suite of cloud-based tools.
    • Cloud Call Center – This service puts Infobird’s years of technical and operational experience to work for clients, with options including intelligent IVR technology, call monitoring, routing strategy and ticketing systems, all supported by multi-dimensional data reports.
    • Intelligent Telemarketing – Infobird’s AI bots can help clients navigate “never-ending lists” of potential customers, filter out the most promising leads and increase the working efficiency of agents, keeping agents focused on high-value tasks.
    • AI Voice Chatbot and AI Text Chatbot – This technology allows clients to create human-like interactions offering 24/7 availability and multi-round dialogue capabilities, decreasing labor costs by up to 80% while greatly improving efficiency.
  • AI Salesforce Management
    • Intelligent Quality Inspection – Infobird’s platform aims to improve quality inspection rates and service levels through the use of real-time smart monitoring with comprehensive coverage.
    • Intelligent Training – Interactive training programs allow clients to ensure and continuously improve the performance level of their agents, lessening the impact of high turnover rates common throughout the customer service industry.

Infobird’s client base includes roughly 10,000 paid user accounts representing 358 customers in the industries of finance, education, public services, consumer products and health care – as reported on June 30, 2020.

Market Outlook

Cloud infrastructure services spending in China increased by 32% ($39.9 billion) in the fourth quarter of 2020. For all of 2020, total services grew to $142 billion, up from the reported $107 billion in 2019. This growth can be attributed to rising demand for cloud infrastructure over physical software solutions (https://ibn.fm/rHZUh). China is the second-largest market for cloud infrastructure solutions after the U.S., accounting for roughly 14% of the global industry.

Likewise, SaaS has demonstrated considerable growth potential in recent years. In 2020, the SaaS industry in China was valued at $3.3 billion, representing an increase of 43.5% over 2019, as companies continue to leverage artificial intelligence and Big Data technologies to increase efficiencies and promote expansion.

As one of the leading and longest standing providers of domestic SaaS solutions and with a comprehensive portfolio of intelligent, customizable and scalable solutions, Infobird is uniquely positioned to capitalize on the market’s expansion and resulting opportunities for corporate growth.

Management Team

Yimin Wu is the CEO and Founder of Infobird. He has served as the Chairman of the board of directors and Chief Executive Officer of the company since it was founded. From August 1990 to March 1993, Mr. Wu was a software engineer for the Software Center of Tsinghua University and was sent to the U.S. to co-develop the HP_UX operating system at HP Inc. From April 1993 to May 2000, he served as the general manager for Beijing Jing Zhou Computers Co. Ltd., a company responsible for marketing and developing interactive voice response systems. From July 2000 to October 2001, Mr. Wu was the general manager for Beijing Jing Zhou Rong Hua Internet Technology Co. Ltd, a company responsible for developing middleware for call center establishments. He received a bachelor’s degree and a master’s degree in computer sciences from Tsinghua University.

Hsiaochien Tseng is the EVP of Infobird and has held the title since January 2020. From March 2010 to September 2018, he served as a sales director for the Credit Card Center of China Guangfa Bank, where he was responsible for integrating and managing online and offline sales channels, establishing overall and regional sales strategies and creating training systems to increase the client base. From October 2018 to January 2020, Mr. Tseng served as SVP of Hua Tuo Digital Technology Group Co. Ltd., a financial information technology company. He received a bachelor’s degree in information management from Fu Jen Catholic University and a master’s degree in business administration from San Diego State University.

Chunhsiang Chen is the VP of Infobird, a position he has held since April 2012. From June 1990 to February 1993, he served as an advisory programmer of International Business Machine Corp. (IBM). During that time, he participated in the design and development of the Multiple Protocol Transport Network. From February 1993 to September 1996, Mr. Chen served as an associate professor in the Information Education Department of National Taiwan Normal University. He founded GenNet Technology Co. Ltd., an information technology company, in 1993 and served as the president until joining Infobird in 2012. Mr. Chen has a bachelor’s degree in computer sciences from the National Chiao Tung University and a master’s degree and doctoral degree in computer sciences from Northwestern University.

Lianfang Zhou is the CFO of Infobird and has been with the company for over 10 years. From September 2004 to July 2008, she served as the head of accounting at Beijing Saishuo Technology Co. Ltd., a software development company specializing in port services. From August 2008 to December 2009, Mrs. Zhou served as the head of accounting for Beijing Lianhe Lida Investment Co. Ltd., a property management services company. She holds an intermediate accounting qualification certificate issued by the Ministry of Finance of the PRC. Mrs. Zhou also has a bachelor’s degree in accounting from the Renmin University of China.

Infobird Co., Ltd (IFBD), closed Friday’s trading session at $3.87, up 2.0327%, on 246,336 volume with 974 trades. The average volume for the last 3 months is 2,229,515 and the stock's 52-week low/high is $3.52399992/$11.25.

Recent News

Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2)

The QualityStocks Daily Newsletter would like to spotlight Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2).

Excellon Resources (TSX: EXN, EXN.WT) (NYSE American: EXN) (FSE: E4X2) has released its financial report for first quarter 2021, the period ended March 31, 2021. The report included both financial and operational highlights. Among the financial highlights for the company was the announcement that revenues had increased by 76% to $9.8 million during Q1 2020 compared to $5.6 million in Q1 2020, and gross profit reached $1.8 million, a $3 million improvement over first quarter 2020, which posted a $1.2 million loss. The company also reported total cash cost net of byproducts per silver ounce payable decreased by 13% to $13.43 compared to $15.35 the same quarter in 2020 and AISC per silver ounce payable decreased by 7% to $24.34 compared to Q1 2020, which was $26.28 or $18.67 excluding non-cash items, the cash component of annual compensation grants and additional electricity costs associated with the mid-February polar vortex. To view the full press releases, visit https://ibn.fm/aX1dS and https://ibn.fm/dhbU8 

Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) (“Excellon” or the “Company”) is a silver and base metals producer with precious metal exploration and development projects in Mexico, Idaho and Germany. Since being founded in 1987, the Company has been advancing a precious metals growth pipeline focused on creating wealth for its stakeholders by realizing strategic opportunities in the silver and gold markets.

Excellon is an active and influential member of the Mining Association of Canada (“MAC”). The Company implements a practical, best-in-class management system that addresses the safety, health, security, environmental and community aspects of its operations, per the UN Sustainable Development Goals. On each project, the Company incorporates MAC’s Towards Sustainable Mining Initiatives and other world-class best practices with the objective of constantly improving its safety systems, training and hazard recognition.

Precious Metals Growth Pipeline

The Company is advancing a precious metals growth pipeline that includes: Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high-quality gold development project in Idaho with strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany, with 750 years of mining history and no modern exploration.

Maintaining and developing this pipeline presents the Company with enhanced opportunities in the expanding precious metals market, which was valued at $193.3 billion worldwide in 2020 (https://nnw.fm/6nv5f). This market is expected to increase at a compound annual growth rate (“CAGR”) of 9% from 2020 to 2027, resulting in an estimated $362.1 billion market size in 2027 (https://nnw.fm/6nv5f). Global market demand was calculated at 22,581.8 tons in 2020 and is expected to grow to 36,501.1 tons in 2027, achieving a CAGR of 3.5% (https://nnw.fm/6nv5f).

Excellon reported strong results in terms of both production and average pricing at the end of Q4 2020, including:

  • Silver – 355,581 oz – $24.46
  • Lead – 2,223,465 lbs. – $0.87
  • Zinc – 2,452,728 lbs. – $1.21

Compared to Q4 2019, Excellon’s silver production increased by 37%, lead increased by 32% and zinc increased by 19% in Q4 2020 (https://nnw.fm/4C0P7).

Platosa Mine – Silver, Lead, Zinc – Production, Development & Exploration

The Platosa Mine is located 5 km north of Bermejillo, Durango, Mexico, on a 14,000-hectare property. The mine commenced production in 2005 as an underground operation and is 100% owned and operated by Excellon. The Company is mining massive sulfide ores rich in silver, lead and zinc from a series flat-lying massive sulfide bodies (mantos) in a carbonate replacement deposit system. Historically, the mining method was a modified room and pillar method, which transitioned to cut-and-fill in recent years and overhand-cut-and-bench in 2020. The ore produced from the mine is transported 200 km south for processing at the Company’s 100% owned Miguel Auza mill.

Kilgore Project – Gold – Exploration & Resource Growth

The Kilgore Project is located in Clark County, situated in eastern Idaho in the United States. The project area is 100% owned and operated by Excellon. While still in the exploration and development phase, the primary target on the 13,627-acre site is an epithermal gold system. The property itself has historical mining that dates back to the 1930s, with modern mineral exploration beginning in the 1980s. The Kilgore Project displays characteristics similar to Kinross Gold’s Round Mountain Mine, which has produced more than 15 million ounces of gold since operations began in 1977.

Evolución Project – Mineral Processing, Resource Growth & Exploration

The Evolución Project is located in Miguel Auza, Zacatecas, Mexico, and hosts a large gold, silver, lead and zinc epithermal within a 45,000-hectare property that is 100% owned by Excellon. The site includes a processing facility with a mill and flotation circuit which processes ore from Excellon’s Platosa mine. The facility has a capacity of 800 tons per day, with a 650 ton-per-day ball mill in operation and a second 150 ton-per-day ball mill on standby. Excellon is looking at opportunities for toll milling, expansion and economic study of the mineral resource and grassroots exploration. Importantly, the project covers an unexplored 35-kilometer strike of the Fresnillo silver trend, the richest silver belt in the world.

Silver City Project – Exploration

Excellon holds an option to acquire the 16,400-hectare Silver City Project in Saxony, Germany. Initial drilling results in 2020 confirmed the presence of a high-grade, district-scale epithermal silver system over more than 12 kilometers of strike. The Company is now focused on defining wider zones of mineralization (https://nnw.fm/jMah9). Silver City was mined from the 11th to late-19th century, until Germany moved off the silver standard in 1873. The deposits in the area were exceptionally high grade, with historical records indicating grades well in excess of 1,000 g/t silver.

Oakley Project – Exploration

The Oakley Project, located in Oakley, Idaho, is an exploration project with land holdings of approximately 7,000 acres. The project hosts gold-silver, epithermal hot spring-type mineralization at two targets: Blue Hill Creek and Cold Creek, and detachment-related gold-silver mineralization at Matrix Creek. The Company has granted Centerra (U.S.) Inc. an option to earn in to a 70% interest by, among other things, spending up to US$7 million in exploration expenditures on the project prior to May 2026.

Management Team

Brendan Cahill is the President & Chief Executive Officer of Excellon Resources Inc. He was previously Vice President Corporate Development of Pelangio Exploration Inc., a junior gold exploration company active in Ghana, West Africa. Mr. Cahill is a board member of the Mining Association of Canada, Group Eleven Resources Ltd., and Kore Mining Inc. He holds a law degree from the University of Western Ontario and an undergraduate degree from the University of Toronto.

Alfred Colas is the Company’s Chief Financial Officer. Most recently, he held the title of CFO of Arch Corp., a Toronto-based private-equity investment firm. Mr. Colas has over 18 years of experience in the mining industry. He is a sitting board member for a housing corporation affiliated with the University of Toronto and is a Chartered Professional Accountant. Mr. Colas completed a Bachelor of Commerce at the University of Toronto.

Paul Keller is Excellon’s Chief Operating Officer. He has over 30 years of industry experience in mining and mine development operations. He previously served as the Senior VP of Major Projects and COO of Trevali Mining. He has experience in building mines from greenfield through permitting, design and operation. Mr. Keller holds a Bachelor of Engineering – Mining from Laurentian University.

Ben Pullinger is the Senior Vice President Geology & Corporate Development for Excellon. Ben brings over 15 years of experience in advancing projects from early stage exploration through to production. Most recently, he was Vice President Exploration at Roxgold Inc., where he made a significant contribution toward growing the 55 Zone at Yaramoko Project into a producing mine. Mr. Pullinger serves on the board of Orford Mining. He is a Professional Geologist (Ontario) and holds an Honors Degree in Geology from the University of Johannesburg.

Excellon Resources Inc. (EXN), closed Friday’s trading session at $2.85, up 9.6154%, on 79,720 volume with 240 trades. The average volume for the last 3 months is 51,265 and the stock's 52-week low/high is $2.19499993/$3.90000009.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today provided a clinical update and business outlook and released its financial results for the quarter ended March 31, 2021. To view the full press release, visit https://ibn.fm/QcOuh

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Friday’s trading session at $1.79, up 4.6784%, on 148,767 volume with 552 trades. The average volume for the last 3 months is 337,392 and the stock's 52-week low/high is $1.59000003/$4.46000003.

Recent News

Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF)

The QualityStocks Daily Newsletter would like to spotlight Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF).

Nextech (CSE: NTAR) (NEO: NTAR) (OTCQB: NEXCF) (FSE: N29), a leading provider of web-based augmented reality for e-commerce, advertising and virtual events, today announced a strategic partnership with Visit Tampa Bay. Designated as a preferred vendor by Visit Tampa Bay, the partnership affords the company the opportunity to connect with confirmed conferences for the city. Nextech is committed to building strategic partnerships with the world’s top destination marketing organizations and extending their reach through virtual and hybrid events. "We are thrilled to partner with Tampa Bay,” said Nextech CEO and Director Evan Gappelberg. “Nextech’s hybrid and virtual events platform keeps audiences engaged with stunning virtual conferences, trade shows, meetings and augmented reality experiences.” To view the full press release, visit http://ibn.fm/Nr2qV

Nextech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF), based in Vancouver, Canada, is a leading provider of web-based augmented reality for e-commerce, advertising and virtual events, with technology ranging from simple 3D images to using 360-degree videos. Nextech AR provides businesses with a powerful end-to-end augmented reality platform designed specifically to increase online sales.

The company is currently pursuing four unique verticals with its innovative technology, including:

  • Virtual Conference Platform: Nextech’s advanced Augmented Reality and Video Learning Experience Platform for Events leverages an SaaS model to give organizations the ability to create engaging virtual event management and learning experiences. Automated closed captions and translations for over 64 languages are available. The global virtual events market was valued at $90 billion in 2020 by Grandview Research, and it’s expected to reach more than $400 billion by 2027.
  • ARitize™ for eCommerce: Launched in early 2019, the company’s SaaS platform for webAR in eCommerce serves as a ‘full funnel’ end-to-end e-commerce solution for the AR industry. The solution includes the Aritize360 app for 3D product capture, ‘Try it On’ technology for online apparel, 3D and 360-degree product views, ‘one click buy’ and much more.
  • ARitize™ 3D/AR Advertising Platform: Launched in Q1 2020, this ad platform is being marketed as the industry’s first end-to-end solution leveraging 3D asset creation for 3D/AR ads. In 2019, according to IDC, global advertising spend totaled roughly $725 billion.
  • ARitize™ Hollywood Studios: The studio is in development as a means of producing immersive content using 360-degree videos and augmented reality as primary display platforms.

Unique Marketing Strategy

Nextech AR’s efforts to disrupt the market for web-based augmented reality for e-commerce are supported by a unique go to market strategy. First, the company seeks to build or acquire platforms targeting a number of rapid growth industries, most notably AR, edTech, e-commerce, 3D/AR advertising and virtual & hybrid events.

After identifying these market opportunities, the company seeks to integrate new AR technologies into existing or novel platforms in an effort to secure market share and promote growth. These technologies include WebAR, Human Holograms, 360 Portals, ScreenAR, Genie in the bottle and AiRShow.

Nextech AR then aims to leverage these platforms to land and expand partnerships with a number of blue chip customers. The company’s current customer base includes the likes of Amazon, Johnson & Johnson, ViacomCBS, Toyota and Carnegie Mellon University.

Growth Capital

Nextech AR generates revenue through a software-as-a-service model from technology services, delivery of service revenue and sales of products through e-commerce.

As noted in its latest investor presentation, the company achieved record bookings in Q4 2020 of $7.3 million (estimated), marking a greater than 275% year-over-year increase. The company also realized greater than 235% revenue growth for calendar 2020, reporting $20 million for the 12-month period. Nextech AR attributes its 2020 increase in revenues to the contracts secured with new customers, expanded agreements with existing customers and additional conversions from e-commerce channels.

With its newly launched 3D ad network now bolstering its operations, Nextech AR is projecting revenues in excess of $50 million for 2021.

Recent Company Highlights

  • February 16, 2021: The company announced it has hired Zak Mcleod, formerly of Fastly, as its new Senior Director of Sales – EMEA. The company also announced that Rory Ganness, formerly of Salesforce.com, has joined the Nextech team as Director of Enterprise Sales – North America.
  • February 11, 2021: The company announced the launch of version 2.0 of its AiR Show app, an application that turns top music artists into interactive ‘live’ holograms, providing an immersive and engaging AR experience.
  • February 8, 2021: The company announced the launch of new standardized chat features within its Virtual Experience Platform (VXP) and recently-launched ARoom collaborative streaming solution. Nextech will also offer the chat platform as a stand-alone SaaS service externally, increasing the company’s revenue potential for 2021.
  • January 26, 2021: The company announced, in partnership with ARB Meetings and Events, it has signed a six-figure annual contract to supply its InfernoAR video conferencing and virtual events platform to NAMD.
  • January 25, 2021: The company announced that Strategic Site Selection (SSS), a 15 year old site selection leader in the meeting and events industry, has selected Nextech AR as a preferred channel partner, making Nextech’s industry leading virtual experience platform and services available to SSS clients.
  • January 20, 2021: The company announced that Microsoft’s Azure Cloud Services platform will be a standard offering across its virtual experience platforms and consumer apps, enabling hyper-scalable, secure and immersive events and applications for users.
  • January 15, 2021: The company signed a renewal agreement with Poly with an initial value of $470,000 for a six-month term and the potential for additional revenue after the six months.

Management Team

Evan Gappelberg is CEO and Founder of Nextech AR. He is an experienced operating executive specializing in creating, funding and running hyper-growth startups in both the public and private sectors. Notably, he took Take-Two Interactive Software Inc. (NASDAQ: TTWO) public with a market cap of $30 million and played a key role in guiding its growth to a current market cap of roughly $14 billion. Mr. Gappelberg has extensive experience as both a hands-on operating executive and a public markets professional.

Paul Duffy is the company’s President. He is a serial entrepreneur with over 25 years of experience in successfully starting, expanding, diversifying and selling global technology companies. Mr. Duffy is the creator of the HumaGram and inventor of the patent for Holographic Telepresence over the Internet (TOIP).

Augen Winschel is the COO of Nextech AR. He is an 18-year SAP executive with over 20 years of leadership experience in the areas of business management, business operations, marketing, product management, digital business and enterprise artificial intelligence.

Kashif Malik, CPA, CA, is the company’s CFO. He has over 15 years of financial experience spanning IPOs, M&A activity, corporate restructuring and capital raising. Mr. Malik has worked globally with public and private companies, including Merck & Company Inc. (NYSE: MRK), Real Matters Inc. (TSX: REAL) and Constellation Software Inc. (TSX: CSU). He obtained his Chartered Accountant designation while working at Deloitte.

Hareesh Acchi is the company’s President of 3D/AR Advertising. He is a 20-year Microsoft technology veteran with experience leading digital transformation and scaling businesses and enterprise organizations across the advertising industry.

Nextech AR Solutions Corp. (NEXCF), closed Friday’s trading session at $1.76, up 13.5484%, on 325,264 volume with 545 trades. The average volume for the last 3 months is 270,807 and the stock's 52-week low/high is $1.50/$5.41120004.

Recent News

Brain Scientific Inc. (OTCQB: BRSF)

The QualityStocks Daily Newsletter would like to spotlight Brain Scientific Inc. (OTCQB: BRSF).

Brain Scientific (OTCQB: BRSF), focused on modernizing the brain diagnostic market through cutting-edge technologies, recently began a collaboration with JelikaLite in a clinical trial. The clinical trial, which has 30 participants from two New York City locations, is designed to potentially uncover new treatment options to reduce autism symptoms in children. “JelikaLite was launched by medical researchers and practitioners specializing in psychology, neurology and phototherapy. The company has developed an innovative solution to potentially reduce autism symptoms and is developing a home-based system that combines a therapeutic wearable device called Cognilum(TM) with an AI-personalized platform. . . Cognilum delivers treatments through transcranial photobiomodulation, also known as PBM therapy. Using an innovative red and near-infrared light treatment, cellular function is stimulated. This type of therapy is already being used for wound healing, tissue regeneration, inflammation, pain management, hair restoration, skin rejuvenation and restoration of normal cellular function,” reads a recent article. “Through the clinical trial, children diagnosed with autism will receive brain treatments through Cognilum while BRSF’s next-generation NeuroEEG monitors brain activity.” To view the full article, visit: https://ibn.fm/wYCUE

Brain Scientific Inc. (OTCQB: BRSF) is a commercial-stage health care company focused on developing innovative and proprietary medical devices and software. With a mission of modernizing brain diagnostics by employing cutting edge technologies to bridge the widening gap in access to quality care, the company offers two FDA-cleared products that provide next-generation solutions to the neurology market.

The company’s proprietary, clinical-grade neurological devices are supported by its intellectual property portfolio featuring patents in the United States, China and Europe.

Brain Scientific’s first commercialized devices, NeuroCap(TM) and NeuroEEG(TM), are designed to disrupt the current electroencephalogram (EEG) market by offering cost-effective and disposable substitutes to existing solutions, allowing medical professionals to collect diagnostic information quickly.

The company’s goal is to improve diagnostics by leveraging artificial intelligence and machine learning processes to analyze a database of brain readings as a method of detecting seizures and dementia. The company is also working to improve patients’ access to neurological care.

Headquartered in New York, Brain Scientific and its predecessor (and now wholly owned subsidiary, MemoryMD Inc.) was founded in 2015 and went public in 2018.

Brain Scientific’s first phase of development, from 2018 to 2019, saw the inception of portable, clinical-grade, easy-to-use neurological devices. The second phase, currently ongoing, aims to create cloud-based, secure infrastructure to transmit patient data between patients and their neurologists. The company’s third phase of development is scheduled for 2021-2022 and is expected to focus on the use of AI-assisted diagnostic analysis to increase the efficiency, consistency and accuracy of neurology specialists.

NeuroCap(TM) – Disposable EEG Headset

The NeuroCap is a disposable pre-gelled EEG headset featuring 22 electrodes and 19 active EEG channels, all adhering to the international 10-20 system. The NeuroCap was FDA-cleared in 2018. The headset can be used for recording EEGs in virtually any setting, including urban and rural emergency departments, neurology clinics, urgent care clinics, ICUs, nursing homes, assisted living facilities and remote clinical research labs.

Through a universal cable adapter, the NeuroCap is compatible with other EEG amplifiers. The cap also works in parallel with Brain Scientific’s NeuroEEG amplifier, initiating EEG studies in less than five minutes.

The company is currently seeking FDA approval for additional features for the NeuroCap, as the device has the potential to fill a gap in EEG testing availabilities during the current coronavirus pandemic: in October 2020, Brain Scientific filed an Emergency Use Authorization (EUA) application. The EUA is required for the rapid distribution of the NeuroCap device to emergency departments, intensive care units and other treatment centers to administer prescriptive EEGs safely on critically ill patients or those suspected of being diagnosed with COVID-19.

With more than 80 percent of hospitalized patients infected with COVID-19 displaying neurological symptoms, the NeuroCap could prove to be a valuable device by offering fast testing with limited contact between technicians and patients.

NeuroEEG(TM) – Miniature and Portable Wireless EEG Amplifier

The NeuroEEG is a compact, portable and affordable wireless EEG amplifier intended for prescription use. The 16-channel, FDA-cleared, clinical-grade device acquires, records, transmits and displays electrical brain activity for patients of all ages.

Both the NeuroCap and NeuroEEG are delivered by MemoryMD Inc., a wholly owned subsidiary of Brain Scientific.

Products in Active Development

Currently, Brain Scientific and MemoryMD are working on leveraging their existing products and drawing from ongoing research to develop and commercialize the next generation of solutions for the brain diagnostics market. The devices under development are being designed to address the following issues:

Routine EEG

  • NeuroCap-8 is an 8-channel EEG cap. The reduced number of electrodes is vital in emergency room situations, where the time it takes to set up the EEG is critical.

Pediatric EEG

  • NeuroCap Pediatric is positioned to become the first disposable and pre-gelled headset available for the pediatric market.

Long-Term Monitoring

  • NeuroCap LTM for adult and pediatric patients is a disposable cap designed to monitor rhythmic and periodic patterns for up to 72 hours, providing essential diagnostic capabilities.
  • NeuroEEG 24 Channel Amplifier is a portable and wireless amplifier with over 24 hours of battery life.

Artificial Intelligence

  • Brain E-Tattoo is a minimally invasive four-channel EEG electrode designed for long-term monitoring.
  • An AI database of brain biomarkers collects data on both normal and abnormal brain data to detect neurological diseases. The goal is for machine learning algorithms to enhance understanding of brain-behavior related to epilepsy, memory dementia and pre-Alzheimer’s diagnostics.

Telemedicine

Brain Scientific is expanding the vision for telemedicine in neurology. The company aims to address the current acute neurologist shortfall (20 states have less than 10 neurologists per 10,000 patients) through the use of teleneurology.

 

Partnership with Marketing Brainology

Brain Scientific has a longstanding partnership with Marketing Brainology, a neuromarketing firm using neuroscience approaches to understand consumer behavior. In 2019, Marketing Brainology conducted a study using NeuroCap and NeuroEEG to determine the most effective Super Bowl commercials.

“Thanks to Brain Scientific’s NeuroCap and NeuroEEG, we are able to better understand the art and science of the human decision-making process,” Michelle Adams, Ph.D, Founder of Marketing Brainology, stated in a news release.

In April 2020, Marketing Brainology again conducted a study leveraging Brain Scientific’s disposable EEG cap to determine how brains were reacting to COVID-19 messaging. Subjects were presented with multiple media impressions, and Marketing Brainology analyzed their responsive biomarkers. The results identified the most effective messaging for engaging with an audience during a crisis.

Market Outlook

The current global market for EEG devices is estimated at $956.1 million. It is expected to rise with a CAGR of 8.7% from 2019 to 2026, reaching $1.6 billion in value by 2026, according to Grandview Research.

In total, there are approximately 6,150 hospitals in the U.S., according to the American Hospital Association. Critically, though, just 254 of those hospitals are certified Level 4 Epilepsy centers with 24/7 EEG coverage. Since very few non-Level 4 centers have extensive EEG tech coverage, this creates a significant opportunity for Brain Scientific to bridge the gap by providing over 5,900 hospitals with lower cost amplifiers and disposable EEG caps.

The company also see opportunities to work with other businesses, such as EEG manufacturers hoping to package Brain Scientific’s solutions with their products, which could greatly expand Brain Scientific’s addressable target market.

Management Team

Dr. Baruch “Boris” Goldstein, Ph.D., is co-founder and Chairman of Brain Scientific. He is a seasoned executive with a proven talent for aligning global business strategies with established and emerging management teams. Goldstein’s growth-focused leadership style has helped him raise over $750 million in venture capital for the development of innovative companies and startups in diverse industries, including financial services, biomedicine, alternate energy and new materials, as well as groundbreaking work in artificial intelligence. His recent achievements include important advancements in neurology and unlocking the potential of AI correlations and machine learning applied to life sciences and medical research. He built a suite of first-to-market companies as a technology-oriented leader, including Ryah Medtech, Brain Scientific, GrapheneCA, E-Forex and Intelligent Video Systems. He also co-founded BrainRX, a company specializing in pre-Alzheimer’s diagnostics.

Dr. Nikolay Kukekov, Ph.D., is a Director of Brain Scientific and a partner at HRA Capital. Before joining HRA Capital, Kukekov was Managing Director of Healthcare Investment Banking at Summer Street Research. His scientific background includes a bachelor’s degree in Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder. He earned his Ph.D. in neuroscience from Columbia University – College of Physicians and Surgeons in New York.

Stuart Bernstein is the company’s Vice President of Marketing. He was recently named to the role after spending the first part of his professional career in senior technical management roles with Fortune 500 companies such as NCR (NYSE: NCR), IBM (NYSE: IBM) and Control Data Corp. He was the CEO of BioSignal, an EEG medical device company. He is also a co-founder of several software engineering and telemedicine firms. One of them, Brain Saving Technology, is now Specialist on Call (SOC Telemed) – a leading telemedicine company that powers over 850 facilities for teleneurology, telepsychiatry and critical care telemedicine with over 200 physicians.

Brain Scientific Inc. (OTCQB: BRSF), closed Friday’s trading session at $1.04, up 15.5556%, on 7,305 volume with 7 trades. The average volume for the last 3 months is 8,400 and the stock's 52-week low/high is $0.550000011/$2.29999995.

Recent News

ISW Holdings Inc. (OTC: ISWH)

The QualityStocks Daily Newsletter would like to spotlight ISW Holdings Inc. (OTC: ISWH).

  • Despite pandemic-related challenges, 2020 was the year of dramatic transformation for ISW Holdings (OTC: ISWH), leading to much bigger expectations in 2021. The global brand management company, which has strategically invested in telehealth and cryptocurrency mining, has issued updates on 2020 financial performance and business plans for the quarters ahead (https://ccw.fm/vghFY).
  • ISW Holdings (OTC: ISWH), a global brand management holdings company with commercial operations in telehealth and cryptocurrency mining, announced that its board of directors has approved the company’s proposed share buyback program. The program has initially been established at $250,000, but the company noted it could be increased in the future. The board approved immediate activation of the program. The program comes following the company’s focus on strengthening its balance sheet through nontoxic fundraising and cash flows from operations. To view the full press release, visit https://ibn.fm/FoCLq

ISW Holdings Inc. (OTC: ISWH), through its in-house initiatives and strategic partnerships, has invested in growing operations targeting the telehealth and cryptocurrency mining industries.

The company specializes in strategic brand development and early growth facilitation. Management maneuvers its proprietary companies through critical stages of market development, including conceptualization, go-to-market strategies, engineering, product integration and distribution efficiency.

Mission

The company’s core mission is to enhance these sectors by implementing innovative services and products that are ready to meet the demands of a changing world. To that end, ISW Holdings leverages its strategic expertise, resources and innovative software to establish market-leading companies and partnerships, thereby ensuring success in their chosen industries.

Cryptocurrency Mining

The start of 2021 saw a massive resurgence in interest surrounding bitcoin and cryptocurrency mining. In mid-February, bitcoin prices hit an all-time high of greater than $57,000, and heightened demand for cryptocurrency mining power has played a key role in exacerbating a global shortage of semiconductors and computer components.

With a foothold in the cryptocurrency mining space, ISW Holdings has placed significant focus on expanding its position and capitalizing on this momentum. Recent highlights include:

  • February 9, 2021: The company announced that its revolutionary Pod5 Cryptocurrency Mining Pod will be powered up into full operational launch at the Bit5ive renewable energy cryptocurrency mining facility in Pennsylvania on February 12, 2021.
  • February 11, 2021: The company announced that it is in negotiations to purchase a large number of miners (between 300 and 900) in preparation for its coming Phase 3 expansion in mining volume.
  • February 23, 2021: The company announced its entry into a comprehensive Hosting and Maintenance Agreement prior to going online with its new ASIC s17 miners.
  • March 2, 2021: The company announced that it has successfully tripled its active cryptocurrency mining fleet with the addition of two new POD5IVE datacenters.

“As we continue to bring our miners online, we want our shareholders to be able to track the expansion and profitability of the company’s mining activity given the sharp rising trend in bitcoin prices,” Alonzo Pierce, President and Chairman of ISW Holdings, stated in a news release. “It currently costs about $11K in computing power to mine a single bitcoin. Bitcoin is pricing at over five times that level, making this is an exceptional ROI opportunity, and our responsibility to our shareholders is clear: continue to invest, expand and execute.”

Business Innovations

ISW Holdings’ diverse portfolio reflects the growing demand for essential services in a dynamic modern operational landscape. Some of the company’s current holdings and partnerships include:

  • Bit5ive LLC: ISW Holdings operates a joint venture with Bit5ive, a global leader in cryptocurrency mining. The joint-venture agreement enables ISW Holdings to collaborate with the experienced team at Bit5ive to innovate the infrastructure needed to run profitable and efficient crypto mining projects.
  • Proceso LLC: ISW Holdings has partnered with Proceso LLC to create high-density processing and mobile data centers powered by renewable energy. These innovations will allow Proceso to offer lower-cost and diverse services to its clients, including hosting and colocation services to growing sectors such as the gaming industry and cryptocurrency mining.
  • PHH Health: The company’s home health division answers the growing need for home care services in a world where health care delivery is changing and an increasingly large aging community is looking for efficient and effective ways of accessing health care.
  • Volum: The company’s logistics and supply chain management division is designed with the core goal of increasing supply chain efficiency, which is recognized as one of the key aspects of successfully growing any business.

Market Opportunity

ISW Holdings’ recent activity in the cryptocurrency mining sector has positioned it to capitalize on the forecast expansion of the cryptocurrency market in the coming years. According to data from MarketsandMarkets, the cryptocurrency space was valued at $1.03 billion in 2019 and is projected to reach $1.40 billion in 2024, achieving a CAGR of 6.18% during the forecast period.

The report suggests that major drivers for this growth will be the transparency of the underlying blockchain technology, the high volume of remittances in developing countries, the high cost of international remittance, expected fluctuations in monetary regulations and sustained investment in the cryptocurrency space by venture capital firms.

Management Team

Terry Williams is the Chief Executive Officer and Director of ISW Holdings. Mr. Williams brings to the company more than 30 years of experience in accounting and information systems, logistics, insurance and transportation. With a Bachelor’s and Master’s degree in accounting and management information systems, he amassed considerable corporate experience at UPS (NYSE: UPS), where he took several logistical roles, managing more than 2,000 employees and a budget of more than $10 billion. Mr. Williams also serves as president of Airware Transportation and Logistics and Chief Financial Officer of AVI Insurance Caribbean. In 2013, he received the National Airport Minority Advisory Council Award for mastering skills in the aviation industry.

Alonzo Pierce is the company’s President and Chairman. He brings a wealth of business development and wealth management experience to the ISW team, having spent the past 20 years building recognizable brands in multiple industry sectors. Mr. Pierce has launched enterprises in life-styled brands which were delivered to high-profile, high-net worth families and individuals. He has worked in the adult beverage industry, establishing a formidable background in marketing and brand creation. Pierce has a B.A. from Baylor University and has received multiple awards in the adult beverage industry, including ‘Outstanding Sales Performance in the Southern Region’ for Sapphire Brands. Pierce also served as a national liaison to a Super-Regional Bank’s private wealth division. In addition to his for-profit endeavors, Pierce has served on multiple charitable boards, sourcing funding for JRA, food insecure families and housing insecure families.

Kristina Mahoney-Brown is Secretary, Treasurer and Director of ISW Holdings. With more than 20 years of experience providing tax and financial consulting to real estate companies, as well as investors, developers and construction companies, Ms. Mahoney-Brown has gained solid business expertise and market knowledge and prides herself on staying abreast of the latest industry trends. Her professionalism, impeccable work ethic and advanced marketing strategies have earned her the nickname ‘The Tax Diva’. Mahoney-Brown has a Bachelor’s in accounting, a Master’s in taxation and a Master’s in business administration, specializing in personal financial planning.

ISW Holdings Inc. (ISWH), closed Friday’s trading session at $0.3125, up 2.3248%, on 618,970 volume with 222 trades. The average volume for the last 3 months is 1,107,269 and the stock's 52-week low/high is $0.0152/$1.47000002.

Recent News

Pac Roots Cannabis Corp. (CSE: PACR) (OTCQB: PACRF)

The QualityStocks Daily Newsletter would like to spotlight Pac Roots Cannabis Corp. (PACR).

Pac Roots (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM) has sought to differentiate itself by focusing on a genetics-based cultivation approach that enables production of premium-quality strains and products. This focus is influenced by the company’s resolution to avoid the fate that has befallen its competitors that have seen recent declines in market share. According to a recent article, PACR’s genetics-based cultivation approach has allowed it “to produce 50 super-elite strains and roughly 350 tested cultivars, which in turn has resulted in the company maximizing yields, boosting profitability and minimizing labor costs. In fact, as Pac Roots CEO explained, the company’s cultivation processes differed radically relative to any of its peers.” To view the full article, visit: https://cnw.fm/3vXE7

Pac Roots Cannabis Corp. (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM) is a Canadian cannabis company dedicated to producing premium-quality strains and products by leveraging a genetics-focused approach.

The company is focused on cannabis and hemp cultivation, leveraging high-end genetics and specialized cultivars to produce top quality products. Pac Roots has announced multiple promising initiatives in recent months since it commenced trading on the Canadian Securities Exchange on May 4, 2020. The company has a partnership with Phenome One, one of the largest live genetic libraries in Canada composed of over 350+ live cultivars, as well as a JV partnership with Rock Creek Farms and Speakeasy Cannabis Club leveraging existing infrastructure, equipment and access to land on a 100-acre hemp project. This combination has the company positioned to be cash-flow positive within its first year of trading.

Furthermore, the company recently completed an agreement to acquire all issued and outstanding shares of a firm holding 250 acres of land in the famed Fraser Valley Region of British Columbia.

Pac Roots is also in the process of completing its 20,000 square foot cultivation facility in Lake Country, British Columbia. The facility is expected to feature approximately 7,600 square feet of cultivation space that will enable the company to cycle through an elite line of 350+ unique, high-grade cultivars. Pac Roots expects to receive a cultivation license for the facility in the fourth quarter of 2020.

High-End Selectively Bred Genetics

Pac Roots focuses on high-end genetics in order to maximize the quality of its products while maintaining high yields and profit margins.

Through the process of artificial selection, farmers and cultivators have been adapting their plants to develop particular phenotypic traits for generations. Historically, this practice was restricted to underground cannabis producers developing their own strains.

The legalization of the cannabis industry has given producers access to thousands of cultivars located throughout the world while accelerating research into cannabis genetics. By carefully selecting strains, growers can control the size, color, smell, density and texture of cannabis buds, thereby creating distinctive, premium cannabis products.

Plants are bred to thrive in specific growing environments. This maximizes the yield of high-quality, resilient cannabis. Medical cannabis strains can also be tailored for specific medicinal purposes.

A strategic partnership with Phenome One, a plant breeding management and analytics firm, gives Pac Roots access to some of the world’s best cannabis genetics from the largest genetic library in Canada. The company is using these genetics to develop unique strains featuring a variety of beneficial characteristics.

The company’s 350+ licensed live cultivars and over 1,800 seed varieties are the result of a meticulous gene selection process, through which as many as 600 individual plants may be grown to produce a single strain. Selecting optimized genetics in this way provides benefits beyond simply producing a high-end product. In addition to potency and bud quality, cannabis plants are bred for yield and resilience. By selecting genetics that result in larger and more numerous buds on each plant, Pac Roots is able to grow more cannabis per grow light.

Breeding plants to be more resilient also reduces the cost and labor required. These factors, combined with the premium price point associated with top-quality cannabis, have the potential to improve Pac Roots’ overall profit margin.

Partnership with Phenome One

Pac Roots has secured its cultivars through a strategic licensing agreement with Phenome One. Under the agreement, Pac Roots has unlimited access to Phenome One’s live genetic library, including any of Phenome One’s cultivars and its growing, breeding and cloning IP.

Phenome One is an agricultural technology company focused on providing software solutions to seed companies. Phenome One’s platform gives its partners access to a massive database of detailed information on over 350 unique cannabis cultivars to support each stage of the breeding process. Each cultivar has been laboratory analyzed and rigorously field-tested, with data going back more than 30 years.

Using Phenome One’s data, Pac Roots plans to grow a variety of cannabis plants optimized for certain traits. One such trait will be plants with an abundance of cannaflavin, a rare terpene with high anti-inflammatory properties. Phenome One’s library could enable Pac Roots to produce plants that are bred to thrive in a range of different growing climates, including plants suited to grow in cold weather and plants that are resilient to region-specific fungi.

Joint Venture with Rock Creek Farms of British Columbia

Pac Roots recently entered a definitive investment agreement with Rock Creek Farms, a reputable agricultural enterprise, for a 100-acre commercial hemp operation in Rock Creek, British Columbia. The growing space is located in the highly lucrative farming area known as the ‘Golden Mile’ in the South Okanagan Valley of British Columbia. (http://nnw.fm/Gbf9I).

Under the agreement, the two companies have formed an outdoor premium hemp joint venture company to which Pac Roots is providing an aggregate of $450,000 in capital and Rock Creek Farms is contributing two commercial leases for 100+ acres of growing space, along with cultivation licenses, agricultural infrastructure and equipment, consulting services, intellectual property relating to hemp operations and proprietary biomass storage methods. Pac Roots holds a 60 percent interest in the project.

About 127,500 premium hemp CBD seedlings were planted across 100 acres as of early July 2020. The joint venture is planting a premium grade CBD hemp variety utilizing the rich native soil and both traditional and custom farming techniques.

“Our operational partners at Rock Creek Farms bring decades of generational farming expertise in one of Canada’s pre-eminent growing regions,” Pac Roots President and CEO Patrick Elliott said in a news release detailing the venture. “It will be an exciting outdoor growing season for the joint venture as we anticipate a successful harvest in the fall.”

Infinite Development Possibilities at Fraser Valley Property in British Columbia

In September 2020, the company announced the closing of a share purchase agreement with 1088070 BC. LTD. (“1088”) and its shareholders for the acquisition of all issued and outstanding shares of 1088 (https://nnw.fm/9gXHk). Through this agreement, Pac Roots gained ownership and control of 250 acres of land spread over nine parcels in the Fraser Valley Regional District.

The Fraser Valley Regional District is one of the most productive and intensively farmed areas of Canada, offering access to high-quality soil, favorable climate, water and a local market of 2.5 million people. Agriculture in this region yields an annual economic value of more than $3 billion.

According to Elliott, the addition of such a significant package of land is a major step for Pac Roots.

“The addition of such a substantial package of land to our portfolio is a major step for Pac Roots. We are pleased to have the opportunity to add significant acreage with an acquisitional cost base of $9,600 per acre. This land has no zoning restrictions and is not situated within the Agricultural land reserve, which provides for infinite development possibilities,” Elliott added in the September 2020 news release.

Board of Directors member Chad Clelland also welcomed the acquisition, adding that between Fraser Valley and Rock Creek – both of them among the most productive agricultural regions in Canada – Pac Roots is very well positioned for production and the future development of its hemp and cannabis infrastructure.

The RAD Americas Genetic Program – Research and Development in Americas Genetic Program

Pac Roots intends to deploy a global R&D program focused on rigorously testing elite strains in various rich agricultural regions throughout the Americas, with a goal of mass selection to achieve the utmost environmental resilience while achieving notable quality and yields. From seed to software, collection data, proprietary techniques and custom nutrient formulas, Pac Roots and Phenome will provide the specific knowledge to cultivators in different climates in order to achieve optimal yields for THC, CBD, CBG and other unique cannabinoids. R&D from global testing programs situated throughout the Americas will allow the partnership to deploy and stress test a range of suitable cultivars in the world’s lowest cost outdoor growing regions.

The company expects an industry shift in 2020 from the COVID-19 global pandemic. The ‘new normal’ will bring more focus on efficiencies and optimal yields to deliver a cost effective, high quality product to the end user. There has been much to be learnt from the inefficiencies in the cannabis industry in recent years, which have been detrimental to the credibility of the sector. Pac Roots is well positioned to enter the scene and take advantage of the deficiencies, reinforcing the notion that genetics and flawless growing techniques are paramount to success. Genetics and systems innovation may be the most overlooked components when comparing cannabis to other established agricultural crops. Pac Roots plans to invest into cannabis R&D to ensure a solid foundation is built that will be used by cannabis farmers worldwide.

Through its RAD Americas Development and Innovation, Pac Roots is focused on:

  • Deploying one of the largest live genetic libraries in Canada, diversified for high yield output and unique climates
  • Continued stress testing for indoor, high yield, THC and medicinal genetics
  • Continued stress testing for outdoor, high yield, THC and medicinal genetics
  • Exotic, genetic cloning for the luxury, high margin, cannabis flower market
  • Psychoactive/medicinal ratio testing for effect and
  • Unique Cannabinoid and terpene elevation and isolation.

Through its RAD Americas Field Testing System, the company is focused on:

  • Global testing in different microclimates to assess genetic and complete systems for optimal yields
  • Data collection, testing and optimization to prove process for commercial implementation and
  • High quality yield testing for THC, CBD, CBG and other unique medicinal cannabinoids.

Lake Country Cultivation Facility near Kelowna, British Columbia

Pac Roots is in the process of completing its 20,000 square foot cultivation facility in Lake Country, British Columbia. The facility is expected to feature approximately 7,600 square feet of cultivation space that will enable the company to cycle through its line of high-grade cultivars. Pac Roots plans to submit a video evidence package of the facility build under Health Canada’s Cannabis Tracking and Licensing System, and the company expects to acquire its cultivation license in the fourth quarter of 2020.

Lake Country is a municipality located just outside of Kelowna in the Okanagan region of British Columbia. For decades, the region’s favorable growing climate has made it a hub for cannabis cultivation. As the Canadian legal cannabis industry ramps up, the Okanagan region is attracting attention from dozens of cannabis companies, including some of the industry’s biggest names. The region’s strong agricultural history has left it rich with experienced agricultural workers and an abundance of Agricultural Land Reserve (ALR) property.

Management Team

Patrick Elliott, MSC, MBA, President and CEO of Pac Roots Cannabis, is also the President & CEO of Lexore Capital Corp., a private resource and cannabis investment company, as well as Phenome One Corp., a full-service cannabis farming company focused on elite strain selective breeding. Elliott brings over 15 years of corporate finance, mineral exploration and financial markets experience to the Pac Roots team. He is a graduate of the University of Western Ontario in geology and holds an MSc. in mineral economics and an MBA from Curtin University of Technology in Perth, Australia. Elliott specializes in economic resource evaluation, financial modeling, CAPEX estimation, corporate development and finance. Combined with his technical knowledge, Elliott has a wealth of contacts in the financial sector.

Marc Geen, Founder and Strategic Operations Advisor, is a fourth-generation British Columbia farmer who has been active in the legal medical marijuana industry for more than 10 years – consulting on, complying with, and participating in the MMAR, MMPR and ACMPR programs. Prior to co-founding Speakeasy Cannabis Club Ltd., Geen spent 14 years as Head of Operations for Kettle Mountain Ginseng Ltd., one of North America’s largest ginseng producers. With the experience gleaned from a long career in large scale commercial farming, Geen has been able to apply many cost-effective farming practices to the outdoor, indoor and greenhouse cultivation of cannabis. Geen is also the co-creator of a full line of cannabis extract products designed under ACMPR regulations.

Matt McGill, Director, has a strong background in both commercial and residential real estate and has played a major role in many development projects. McGill, through McGill Realty, has established a tremendous commercial and residential outfit servicing British Columbia’s Fraser Valley and the lower mainland. McGill is skilled at crafting strategic financing options for corporations and has a substantial network of retail and institutional clients.

Chad Clelland, Director, has experience in the sector dating back to 2009, when he purchased Medicalmarijuana.ca, which became an information portal for thousands of patients, doctors and growers. Through this company, he and his team have helped thousands of Canadians find legal, safe medication. His team also consulted, designed and submitted dozens of applications to the government under the MMPR, ACMPR and Cannabis Act. In 2011, Clelland co-founded Greenleaf Medical Clinic, which is now recognized as a training facility by the University of British Columbia and offers preceptorships to physicians, nurse practitioners and pharmacists. He also co-founded Folium Life Science in 2013, an approved Canadian Licensed Producer. His roles in these organizations have included Chief Operating Officer, head of security, alternate master grower and alternate responsible person in charge.

Josh Bromley, Senior Cultivation Strategist, is a second-generation farmer with over two decades of experience farming, breeding, cultivating and selecting unique cultivars for the medical community. He is an expert in plant science and possesses a comprehensive knowledge of cultivars and a mastery of medicinal implementation. Bromley has developed proprietary farming systems, as well as low cost/high output nutrient systems. Through thoughtful design and engineering, he has been able to consistently show improvements in crop yields, pathogen resiliency and quality.

Pac Roots Cannabis Corp. (PACRF), closed Friday’s trading session at $0.1532, up 6.7596%, on 2,000 volume with 2 trades. The average volume for the last 3 months is 3,083 and the stock's 52-week low/high is $0.009999999/$0.204500004.

Recent News

Healthtech Solutions Inc. (OTC: HLTT)

The QualityStocks Daily Newsletter would like to spotlight Healthtech Solutions Inc. (OTC: HLTT).

Healthtech Solutions (OTC: HLTT), focused on acquiring and investing in strategic cutting-edge health care technological opportunities, is among biotech players that have pivoted to a new model wherein multiple portfolio companies operate under one parent organization. Healthtech’s latest acquisition, Varian Biopharmaceuticals, brings to three the number of subsidiaries under its umbrella. “The acquisition of Varian by Healthtech plays to the strengths of the new portfolio model not only in drug pipeline but also by bringing in experts in an area that could attract additional investment,” reads a recent article. A precision oncology company, Varian specializes in developing atypical protein kinase C iota (“aPKCi”) inhibitors for different tumor types. Its two lead candidates are being prepared for clinical trials. The article quotes Healthtech CEO and Chairman David Rubin as saying, “The fact that [Varian Bio is] developing therapies to target difficult-to-treat cancers such as pancreatic cancer demonstrates just how innovative their team is.” To view the full article, visit https://ibn.fm/Wi77m

Healthtech Solutions Inc. (OTC: HLTT), through its Mediscan Inc. subsidiary, created a cloud-based software for ultrasound technology that reconstructs the analog two-dimensional grayscale visual image into a digital three-dimensional, high-definition quantifiable format.

The Mediscan software application dramatically increases the medical professional’s ability to use existing ultrasound devices at the point of care to derive meaningful data-driven clinical evaluations of a patient’s pathology or trauma, facilitate support for treatment options, monitor the patient’s ongoing progress or regress, and document compliance with required protocols and procedures. The Mediscan application also integrates with all popular EMR systems.

Healthtech Solutions Inc. acquired all of Mediscan’s capital stock in a reverse acquisition transaction on November 13, 2020. On November 23, 2020, the shareholders of Healthtech Solutions Inc. consented to a resolution changing its name to Healthtech Solutions Inc.

The company’s operational focus for the immediate future will be on Mediscan’s continuing research and development of imaging, development of other medical solutions, and making strategic investments.

Mediscan Technology

Mediscan software transforms an ultrasound analog 2D grayscale image into a digital 3D HD format. When paired with a portable ultrasound machine, the software application can enable these detailed and quantifiable scans by on-the-scene medical professionals, such primary care physicians, specialists and technical support staff, as well as sports trainers, emergency medical services (EMS) personnel, and technicians in isolation wards and emergency rooms.

Once an image has been captured in 2D, it is converted using a cloud-based software application process – a process that takes approximately one minute. The completed 3D image is viewed on the medical professional’s computer monitor, pad or smartphone at the point of service. This technique can generate 3D medical images of different organs, such as the heart, lungs, tendons, skin and nerves.

This cloud-based software application for ultrasound devices is easy to use anywhere there is an internet connection. The application provides the convenience of point of care ultrasound with the image quality of CT or X-ray and the safety of very expensive MRI technology. For patients, it provides a convenient and comfortable medical experience.

Mediscan has filed two patent applications with the United States Patent and Trademark Office, both for a System Method, Apparatus, and Computer Program Product for Ultrasonic Clinical Decision Support (https://ibn.fm/lpImS).

The technology will initially be available as medical software-as-a-service (SaaS), resulting in cost-efficiency. The SaaS model eliminates the customer’s need for external hardware and software solutions, as well as technical maintenance. The SaaS model is already widely used in the health care industry, most notably for clinical information systems and supply chain management, revenue cycle management and billing. Benefits include increased patient and physician satisfaction, lower operational costs, better workflows and more. Per company data, the Mediscan system is fast and efficient, which could generate a significant cost reduction.

Health and Wellness Applications

Mediscan’s technology has shown success in musculoskeletal (MSK), lung and cardiac imaging, enabling rapid pathology evaluation. Scanning the lung and or the MSK sub-system, the application directly images the target area, saves it as a reference, and then compares it to previous images, helping to determine if the patient is progressing or regressing.

The cardiac application combines imaging with a therapy system that detects and classifies cardiac myopathy conditions via an “entrainment” process similar to that used in treating tachycardia. This application also features a comparison function where the latest imagery is interpreted against previous vetted cardiac images to detect progression or regression.

Mediscan’s technology can also be utilized on the wellness market for diagnostics and support in a wide range of situations, such as sports injuries, physical therapy and dermatological indications.

COVID-19 Applications

COVID-19 causes complications with patients’ cardiovascular and pulmonary systems. Mediscan’s technology could help meet the growing need for advanced diagnostic and monitoring imaging at the point of care.

Portable ultrasounds equipped with Mediscan’s application are a flexible and easy-to-use solution for health care providers to evaluate, triage and diagnose COVID-19 effects on contagious patients in isolation where MRI, CT or PET Scans are not accessible. With this technology, health care providers can easily detect lung lesions or heart muscle shredding, which often appear in patients with COVID-19.

Diagnostic Imaging Market Outlook

With the increasing demand for early diagnosis and a widening scope of clinical applications, any promising technological advancements in the field constitute a significant investment opportunity. The global market is also being driven by technological advances in the diagnostic imaging industry.

As standard ultrasound 2D greyscale images are generally the norm, and 3D imaging typically requires the use of CT, PET, MRI or X-ray technology, Mediscan’s application could have a dramatic impact on the medical imaging industry, meeting the need for imaging equipment and devices that can generate human anatomy data in 3D.

The global market for diagnostic imaging was estimated at approximately $100 billion in 2016 (https://ibn.fm/xtInK) and was expected to grow steadily, creating a promising opportunity for Mediscan to distribute its technology and achieve its mission as a developer and distributor of medical imaging solutions designed for both long-term care and acute and emergency medical services.

Management Team

David Rubin is the Chairman and CEO of Healthtech Solutions Inc. Mr. Rubin has been in the financial services business for over 20 years. Concurrently, he is also the CEO of Capital Stack LLC and CEO of eProdigy Financial LLC. Rubin attended Kingsborough Community College from 1985 to 1988.

Manuel Iglesias is the President and a Director of Healthtech Solutions Inc. Mr. Iglesias has practiced law since 1980, specializing in business law, merger and acquisitions, securities and health care. Mr. Iglesias served as President, CEO and a board member of Hygea Holdings Corp., which provided primary care medical services throughout Florida and Georgia. He served as the National Chairman of the Republican National Lawyers Association in 2019 and 2020. Mr. Igleisias was awarded his MBA degree from the University of Chicago in 1981, a Juris Doctorate from the University of Chicago in 1979, and a BS in Foreign Service from Georgetown University in 1976.

Denis Kleinfeld is a Director of Healthtech Solutions Inc. and General Counsel and a Director of Mediscan Inc. Mr. Kleinfeld has extensive experience in business planning and regulatory compliance. Mr. Kleinfeld is a renowned expert in international tax and estate planning law. Kleinfeld received his Juris Doctorate from the Loyola University of Chicago School of Law in 1970.

Richard F. Parker is the Chief Research Officer of Mediscan Inc. He developed the technology that is the foundation of Mediscan’s business plan. Before he joined Mediscan, Mr. Parker was employed as an engineer and business executive for 37 years. Previously, he was President and Chief Technology Officer of CytoWave LLC. Mr. Parker was awarded a patent for technology that supported a Method and Apparatus for Generating a Therapeutic Magnetic Waveform. During the past 10 years, Mr. Parker has published 14 papers and made numerous presentations focused on magnetic imaging and treatment of sports and equine injuries. He obtained his MSEE degree from the Georgia Institute of Technology in 1971.

Healthtech Solutions Inc. (HLTT), closed Friday’s trading session at $1.00, even for the day, on 500 volume. The average volume for the last 3 months is 24,239 and the stock's 52-week low/high is $0.025/$4.00.

Recent News

Mobius Interactive Ltd.

The QualityStocks Daily Newsletter would like to spotlight Mobius Interactive Ltd..

Mobius Interactive, an online Esports and gaming operator, is expanding into the Brazilian market. The Company announced in a recent press release (https://ibn.fm/Pj2uL) that the Mobius.Bet brand will be displayed prominently in every stadium and on Globo TV for all eight World Cup qualifiers in Latin America. Soccer is the biggest sport in the world and Brazil is a soccer powerhouse. Brazil holds more World Cup victories than any other team; they have qualified for every World Cup they have entered.  

Mobius Interactive Ltd. is an online gaming operator launching in September 2020 with a variety of unique offerings catering to diverse demographic groups. In partnership with Ultra Play, a leading eSports and iGaming platform, Mobius Interactive is seeking to attract a network of high-net-worth gamers from around the world through the use of loyalty and gamification programs designed to enhance customer engagement by leveraging state-of-the-art customer relationship management systems and joint-ventures with over 600 VIP and Master gaming affiliates.

Array of Brands

Mobius Interactive is seeking to target a variety of customer segments and geographies through its diverse brand offerings, including:

  • Aragon Casino: Austria, Finland, the Balkans, Canada, Africa and New Zealand
    Catering to consumers aged 21 to 45, Aragon Casino brands itself along the lines of medieval fantasy, mimicking elements from the likes of The Walking Dead and Game of Thrones.
  • Club Double: Austria, India, Brazil, Finland, Canada, Africa and New Zealand
    Targeting the 30 to 65 age demographic, Club Double is designed to exude a classic yet magical old Hollywood and vintage Miami & Las Vegas air.
  • MobiusBet: Germany, Austria, Switzerland, Brazil, Latin America, New Zealand and India
    MobiusBet is designed to appeal to the 18- to 38-year-old eSports community, bringing together loyalty programs, targeted gamification and product merchandising in one seamless package.

Key Differentiating Indicators

Mobius Interactive has designed its platform with a number of key differentiation traits relative to its target market. These include:

  • The use of affiliates: Mobius Interactive has partnered with over 600 VIP and Master gaming affiliates, who will introduce high-value players to the company’s award-winning iGaming platform. Mobius added over 150 proven affiliates in Europe, Brazil, Finland and New Zealand over a period of just 20 days.
  • eSports Focus: Mobius.Bet, Mobius Interactive’s dedicated eSports hub, will cater to the quickly growing eSports segment, which is expected to rise to a value of $1.7 billion in 2021. With Mobius’ COO being one of the original founders of the eSports.com brand, the company aims to capitalize on this growing segment of the gaming industry.
  • Customer Relationship Management (CRM): Mobius has partnered with Solitics, a new and real-time CRM system, enabling the company to personalize customers’ gaming experiences in an interactive and highly intelligent manner.
  • Loyalty & Gamification: Mobius Interactive is set to introduce a unique loyalty and gamification program designed to increase customer engagement from signup. Loyalty and gamification programs have been proven to increase daily active wagering volumes by 30% while simultaneously increasing daily player activity by 60%. Furthermore, the introduction of these programs can help lower the company’s customer acquisition costs while adding a differentiating element to its platform.

Partnership with Puurl

Puurl provides a solution that embeds eGaming platforms into any existing online e-commerce store. First, shoppers can install the Puurl add-on to their browsers. Then, when visiting their preferred e-commerce stores, players will be prompted to bet, with the potential to win the products they’re browsing. The Puurl solution enables e-commerce operators and eGaming platforms to earn additional gambling revenues – even when their players are shopping. Through its partnership with Puurl, Mobius Interactive will look to add a unique revenue stream to complement its core business operations.

Management Team

Lynn Pearce, CEO, is an experienced, data-driven, commercially focused, strategic brand marketer with over 15 years of proven success in the global gaming industry, from land-based casinos in the UK to online gaming companies offering sports betting, poker and casino games. She was head-hunted to join a startup in Prague that launched 26 casinos, becoming profitable within the first three months of operation, before she relocated to Malta to join a leading B2B casino software development company as head of marketing, where she led global marketing, PR, product development, branding and go-to-market campaigns, retaining full control of a six-month budget of €1 million to increase brand awareness and customer engagement. She recently returned to the B2C side of gaming to launch three new brands in Germany, Brazil and India. She writes articles regularly for Infinity Gaming Magazine and has been a judge for the prestigious International Gaming Awards, a significant event for the gaming industry held each year prior to the largest gaming exhibition of the year, ICE London.

Robin Lawson, Vice President & COO, has been involved in iGaming for over 10 years, successfully founding two VIP casino departments across international locations in Latin America, as well as startup company Tabella in Europe. He most recently co-founded and acted as COO for eSports.com, which raised over $5.5 million as a startup ICO and was sold to German media giant ProSieben. Lawson is also a senior iGaming consultant for startup casino groups and an advisor to blockchain-based tech groups. His long-time experience and proven track record in startup organizations demonstrate his operational leadership skills.

Nicholas de Freitas, Vice President, Marketing, is one of the pioneers of digital stills photography for major retail companies in Africa and Australia. He left to start up UrbanActive, an outsourcing agency, working as marketing project manager and implementing major retail projects. He received his certification in digital marketing from the University of Stellenbosch. He has worked over the past few years as the marketing manager for various poker rooms and casinos, liaising and building relationships with software developers, successfully implementing a number of casino and poker products and holding regular weekly report sessions with the heads of all divisions of the company, spanning South Africa, Canada, Malta, Norway and Costa Rica.

Gary Eldridge, Chairman, is an experienced entrepreneur with a history of working in the venture capital and private equity industry. He is skilled in capital markets, M&A and funding startups and is a strong business development professional. For the past 30 years, he has created and managed numerous public and private companies in Canada, the U.S., Amsterdam, London, Zurich, Dusseldorf, Singapore and Panama. In addition to holding the role of chairman of the company, Eldridge is acting as a mentor to the team, assisting with the financials and structure of the company while allowing the team to be fully focused on Mobius’ growth and operations.

Recent News

chart

First Energy Metals Ltd. (CSE: FE) (OTCQB: FEMFF)

The QualityStocks Daily Newsletter would like to spotlight First Energy Metals Ltd. (CSE: FE) (OTCQB: FEMFF).

First Energy Metals Ltd. (CSE: FE) (OTCQB: FEMFF) (WKN: A2JC89)  (" First Energy" or the " Company ) was pleased to announce that it has granted incentive stock options to certain directors, officers and consultants to purchase up to an aggregate of 850,000 common shares under the Company's Incentive Stock Option Plan. The options will be exercisable for a period of five (5) years, at an exercise price of $0.35 per share and are subject to Canadian Securities Exchange approval.

First Energy Metals Ltd. (CSE: FE) (OTCQB: FEMFF) is a publicly traded Canadian mineral exploration company. Its primary focus is on developing a multi-commodity mineral property portfolio by identifying, acquiring and exploring North American mineral prospects in the precious metal, base metal and industrial metals sectors.

Headquartered in Vancouver, the company (formerly known as “Agave Silver”) was first incorporated on October 12, 1966.

Core Properties – Augustus Lithium and Titan Gold

Located in Landrienne & Lacorne-Townships, Quebec, Canada, in an active lithium exploration/mining area, the Augustus Lithium Property and surrounding claims total 14,367.71 hectares . It is equipped with excellent infrastructure support, including a road network, railway, electricity, water and trained manpower available locally.

Other highlights of the Augustus Lithium Property include:

  • Geologically similar to Sayona Mining’s Authier Lithium project and Mine Quebec Lithium project located 6-12 km away.
  • Documented historical drilling over 10,000m in 62 drill holes, worth over $2 million in present day exploration expenditures.
  • Two prominent lithium and one silver prospects located on the property.
  • A potential high grade lithium resource target of 4 million tonnes at 1% lithium oxide (Li2O).
  • Potential for large volume low grade bulk tonnage near surface.
  • Two phase exploration work program includes: data compilation, geological mapping, trenching and sampling in Phase 1 (estimated cost $191,418) and diamond drilling, metallurgical testing and resource estimation in Phase 2 (estimated cost $1,166,963).

The Titan Gold Property is located in the Detour-Fenlon Greenstone Belt of east-central Quebec and is comprised of 80 mining claims totaling 4,334 hectares.

Other highlights of the Titan Gold Property include:

  • The Detour-Fenlon Greenstone Belt is host to the Detour Mine containing 20 million ounces of gold. The Fenlon Project of Wallbridge Mining has also reported strong high-grade gold intercepts and a successful high-grade (18.49 g/t Au) bulk sample.
  • Hosted within a structurally active geological environment with several northwest trending deformation zones which are splays off the Sunday Lake Deformation Zone – all key ingredients to the gold mineralization in the area.
  • The property has seen little historical exploration yet sits within what is becoming a prolific recognized gold camp.

Non-Core Properties – Kokanee Creek Gold and Scramble Mine Properties

The Kokanee Creek Gold Property consists of three mineral claims covering approximately 1,590.29 hectares in the Nelson Mining Division in British Columbia.

Other highlights of the Kokanee Creek Gold Property include:

  • Gold mineralization indicated in surface samples from historical work since 1979.
  • Subsurface gold mineralization discovered in drill holes.
  • Continuity of mineralized zones indicated through geological mapping, geochemical and geophysical survey.
  • Past producing mines in the vicinity, including the Molly Gibson and the Alpine deposits.
  • Historical production reported for the Molly Gibson Mine from 1909-1940 was at an average grade of 36.1 g/t Au and 15.3 g/t silver, with recent exploration returning samples running up to 270 g/t Au.
  • Revived exploration on the Alpine deposit area has reported a 2018 inferred resource of 142,000 oz at 16.52 g/t Au using a cut-off grade of 5.0 g/t.

First Energy Metals also holds an option to acquire a 100% interest in the Scramble Mine Gold property, located approximately 8 km east of the town of Kenora in Northwestern Ontario. The mine was discovered in 1894 but remained essentially dormant until 1984, when Boise Cascade Canada Ltd. commenced an evaluation of the property. Since 1984, approximately 5,200 meters of diamond drilling, 250 meters of surface stripping with sampling and 450 meters of underground development have taken place at the property.

Other highlights of the Scramble Mine Property uncovered as part of the company’s 2020 prospecting and sampling programs include:

  • Average value of gold in surface samples is 29.34 grams per tonne (1.03 ounces per tonne).
  • Gold assays ranged from 5.03 grams per tonne (0.18 oz/t) to 82.30 grams per tonne (2.90 oz/t), with two samples assayed over 2 oz/t.
  • All samples assayed over 5 grams per tonne gold.

Market Outlook

The global precious metals market was valued at $193.3 billion in 2020 and is expected to grow at a CAGR of 9%, resulting in a market valuation of $362.1 billion by 2027 (https://ibn.fm/WvN9Z).

The global lithium metal market was valued at $534.6 million in 2020. Through 2027, it is expected to grow at a CAGR of 9.6%, resulting in a forecast valuation of $926.6 million (https://ibn.fm/xBXcx).

First Energy Metals is well positioned to leverage growth opportunities in these expanding sectors through exploration of both its core and non-core properties.

Management Team

Gurminder Sangha is the Chief Executive Officer and Director of First Energy Metals Ltd. He is experienced in the financial industry, focusing on providing advisory-level services to privately and publicly traded companies. Mr. Sangha brings over 18 years of diverse experience related to financial management, business leadership and corporate strategy to his role with First Energy Metals. During his tenure as a board member for various publicly traded companies, he has led initiatives related to corporate finance, business development and corporate governance. Mr. Sangha has an MBA from both Queens University and Cornell University.

Jurgen Wolf is the Chief Financial Officer and Corporate Secretary for First Energy Metals Ltd. He has been involved in the oil and gas industries for over 15 years, assisting public companies with administration and investor relations. Mr. Wolf was educated in Germany and immigrated to Canada in 1953. From 1958 to 1982, he owned and operated pre-cast concrete factories in Calgary and Vancouver. From 1982 to 2002, Mr. Wolf owned and operated J.A. Wolf Projects Ltd., a commercial construction company. He is the previous President and Director of the former US Oil and Gas Resources Inc., which amalgamated to form Petrichor Energy Inc. in 2005. Mr. Wolf retains director roles with several public companies.

First Energy Metals Ltd. (CSE: FE) (OTCQB: FEMFF), closed Friday’s trading session at $0.266984, off by 6.0246%, on 3,724 volume with 8 trades. The average volume for the last 3 months is 21,533 and the stock's 52-week low/high is $0.085100002/$0.45719999.

Recent News

Golden Leaf Holdings Ltd. (CSE: GLH) (OTCQB: GLDFF)

The QualityStocks Daily Newsletter would like to spotlight Golden Leaf Holdings Ltd. (CSE: GLH) (OTCQB: GLDFF).

Golden Leaf Holdings Ltd. (CSE:GLH) (OTCQB:GLDFF) (“Golden Leaf” or the “Company”), operating as Chalice Brands, a premier, consumer-driven cannabis company specializing in retail, production, processing, wholesale, and distribution, today announces it will report its first quarter 2021 results before market open on Tuesday, May 25 th , 2021.

Golden Leaf Holdings Ltd. (CSE: GLH) (OTCQB: GLDFF) is a premier consumer-driven cannabis company powered by the Chalice retail and consumer brands. GLH takes a diversified approach to growth through innovation, strategic partnerships and retail expansion, as well as a brand portfolio focusing on health and wellness. The company features best in class retail cannabis experiences backed by cultivation, processing and developing wholesale distribution. With over 160 employees, GLH is one of the largest cannabis operators in Oregon. The company holds licensing in Oregon, as well as partnerships for manufacturing and distribution in California. Its current product portfolio includes recognizable brands such as Chalice(TM), Elysium Fields(TM), GOLDEN(TM), Jackpot(TM) and RXO(TM).

Brands

Golden Leaf Holdings offers an innovative product line that addresses current market needs and looks forward to meet emerging trends. The company’s goal is to offer something for everyone through the wholesale and retail marketplaces. Its current product offerings include:

Chalice(TM)

The Chalice Farms(TM) brand is focused on how cannabis enhances lives and ignites purpose. By offering the highest quality of cannabis in an array of flower, extracts, oils, edibles and full-body care products, the brand provides full efficacy in both the retail and wholesale markets. The Chalice Farms team has over 100 years of combined cannabis experience and continues to be an industry leader for both medical and recreational cannabis use – providing state-of-the-art farming practices, excellent retail and complete product innovation.

Elysium Fields(TM)

Elysium Fields(TM) is a “soil-to-oil” craft cannabis brand intended for cannabis connoisseurs who want the highest quality THC and boldest terpene flavors. Made from small-batch live resin, Elysium Fields creates an experience described as a remarkable entourage effect. The C-Cell cartridge has a 30% strain specific HTE with a 70% high THC distillate. The resin is created from a sustainable, organic garden flower that is flash-frozen upon harvest to preserve the terpenes for a heavenly experience.

RXO(TM)

RXO(TM) features Chalice Farms’ purest and most versatile Rick Simpson Oil products. RXO was developed by the Steele brothers in collaboration with medical professionals and is a potent, strain-specific Ethanol Hash Oil (EHO) purified through a proprietary process. Through this process, various consumption methods can be accommodated, including edible, topical, sublingual and smoking (shatter and vape).

GOLDEN(TM)

GOLDEN(TM) offers a wide variety of craft cannabis products for a diverse population of cannabis users. Sourced from the finest raw materials from local growers, GOLDEN products are high-quality and innovative. Premium cannabis distillate vaporizer cartridges and fruit chew edibles made from organic ingredients are made using the most flavorful terpenes for enhanced health, wellness and enjoyment. Products are distributed online and through Chalice Farms or other dispensary partners.

Jackpot(TM)

Jackpot(TM) products offer a powerful combination of flavor and potency. With 70% THC content in each cartridge, Jackpot adds full-spectrum cannabinoids and flavorful infused terpenes in short-run limited strains for on-the-go fun seekers. The quality hardware of the cartridges makes them easily recyclable and guarantees to produce a large volume draw each time.

Cannabis Market Outlook

In 2020, the legal cannabis market was valued at approximately $23 billion, and it is expected to top $73.6 billion in revenue by 2027, growing at a CAGR of 18.1% during the forecast period (https://ibn.fm/LdkhG). One of the biggest factors driving the cannabis market’s growth is legalization around the world.

As cannabis sales generally increased during the pandemic, Golden Leaf Holdings achieved record financials for Q3 2020, reporting quarterly revenue of $6.2 million, a year-over-year increase of 42%. For the first time in its history, the company also reported positive cash flow in excess of $417,000 (https://ibn.fm/LY1b2).

Golden Leaf Holdings is uniquely positioned to capitalize on the growth of both the medicinal and recreational marijuana market segments through a rich product offering that successfully addresses current consumer needs.

Management Team

Jeff Yapp is the CEO and President of Golden Leaf Holdings Ltd. He has created a culture at GLH that operates under his mantra of ‘Crawl, Walk, Run’. He is an accomplished entrepreneur and corporate executive who has built a successful career through his ability to recognize opportunity, even when it isn’t obvious. Mr. Yapp has an extensive background in retail, marketing and entertainment. In the past, he has been committed to bringing innovation to Fortune 25 companies such as Microsoft, Kraft Foods, PepsiCo and more. As a strategic partner for Microsoft, he is an integral driver of growth for online and retail operations. He graduated with honors from the University of Michigan, majoring in Business Administration. He also graduated with honors from JL Kellogg School of Management at Northwestern University.

John Varghese is the Executive Chair of Golden Leaf Holdings and is responsible for all capital markets initiatives at GLH. His background is in mergers and acquisitions, investing, operations and capital markets, with professional experience that ranges from private equity, venture capital and investment banking to senior management positions and director roles in both private and public companies. He has served on over 20 boards, acting as the chairman of six of them.

Andrew Marchington is the company’s CFO. His public accounting career experience includes time with start-up, high-growth and enterprise-level organizations, including five years of prior cannabis industry experience. He has a rich understanding of the priorities and best practices within accounting, finance and management. Mr. Marchington’s past experience includes time with companies like Deloitte, Moss Adams, Cambia Health Solutions and C21 Investments.

John Ford, Golden Leaf Holdings’ Chief Revenue Officer and VP of Retail, is a seasoned and dynamic retail leader with extensive experience in the retail industry who has led the launch of major retail brands such as Apple and Microsoft in China and Australia. His goal is to help retailers transition their businesses to modern experiential locations where customers can engage with products and brands in new ways. At Apple, Mr. Ford was the only field expat sent to launch Apple Retail in China. He set several records for Apple while in China, not just in sales but also in inventory management and employee turnover. Mr. Ford left Apple to lead Microsoft’s international retail expansion, where he also managed its e-commerce presence.

Golden Leaf Holdings Ltd. (GLDFF), closed Friday’s trading session at $0.047448, off by 3.1673%, on 1,423,567 volume with 140 trades. The average volume for the last 3 months is 1,791,097 and the stock's 52-week low/high is $0.0098/$0.088100001.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

closed Monday's trading